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1 Introduction 
 
 
1.1 Multiple sclerosis (MS): An introduction 
Multiple sclerosis has been the oldest described and one of the common 
organic neuropathy in Europe, for more than 500 years. Even after 160 years since the 
pathological and anatomical description by Cruveilhier and Carswell, and more than 
150 years after the establishment of MS as a pathological and clinical entity by 
Charcot (Charcot, 1868; Charcot, 1877; Höher PG, 1985), the etiology of this disease 
is still unknown. 
The latest knowledge of the pathogenesis of MS is at the best summarized as a 
combination of an infection and autoimmunity especially directed against neural 
antigens e.g. myelin basic protein (MBP), and disturbance of immunoregulation in 
genetically susceptible humans (Barnett and Sutton, 2006; Ibrahim and Gold, 2005; 
Thacker et al., 2006). This results in local and temporary disseminated demyelination 
especially of the white matter and axon loss of the central nervous system (CNS) 
mainly associated with inflammation; leading to the name multiple sclerosis. 
MS is a heterogeneous disease: acute and chronic, exacerbations and 
remissions, and manifold clinical symptoms.  
  
1.2 MS types 
There are two major forms of MS: (1) relapsing remitting (RR) and (2) 
primary progressive (PP) (Sospedra and Martin, 2005). RR is the most frequent form 
of MS (85–90 %) which is characterized by discrete clinical “attacks” or “relapses” 
often followed by subsequent improvement. This type is common in young women 
(Keegan and Noseworthy, 2002). 
After several years of onset, RR may develop into secondary progressive (SP) 
form. In this condition patients develop a slow, insidiously progressive neurological 
deterioration over many years with or without clinical “attacks” superimposed. 
About 10–15 % of the patients suffer from PP, which is characterized by a 
progressive course from onset, an absence of clinically evident relapses. The 
underlying pathology of PP is thought to be different from RR. It could be a 
degenerative form rather than inflammatory. It is still not clear what factors are 
responsible for the different courses.  
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1.3 Pathological hallmarks and neurological symptoms 
Four immunopathological subtypes of MS lesion have been reported: (1) 
inflammation with T cells, B cells and macrophages/microglia, (2) demyelination with 
oligodendrocyte loss during chronic disease stage and a variable degree of 
remyelinataion, (3) axonal loss and (4) gliosis with astrocyte proliferation and 
intensive glial fibre production (Bruck and Stadelmann, 2005).  
The mechanisms of tissue damage in MS lesion are not yet fully understood. 
Gross examination of MS brain tissue reveals multiple, sharply demarcated plaques in 
the CNS white matter with a predilection to the optic nerves and white matter tracts of 
the periventricular regions, brain stem, and spinal cord. Example of lesions in the 
brain of a MS patient is given in Figure 1. 
 
 
 
 
 
 
 
 
 
Figure 1 This magnetic resonance imaging scan shows multiple abnormal white 
areas that correspond to multiple sclerosis plaques (lesions). Each arrow 
shows the lesion. 
 
However, a new paradigm proposes that oligodendrocyte apoptosis is the 
earliest change in newly forming lesions and that tissue injury is later on amplified by 
the subsequent recruitment of a systemic immune response (Barnett and Sutton, 
2006). 
Neurological symptoms in MS reflect the location of the lesion within the 
CNS for example visual loss reflects a lesion of the optic nerve; hemi-, para or 
quadriparesis, with or without bowel/bladder dysfunction reflects a lesion of the 
spinal cord; vertigo reflects a lesion of the brain stem and ataxia, and cerebellum 
(Keegan and Noseworthy, 2002). There are other symptoms like debilitating fatigue, 
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paresthesias on neck flexion (Lhermitte’s sign), and heat exacerbated symptomatic 
worsening (e.g.Uhtoff’s symptom) may be present.  
 
1.4 Pathogenesis of MS 
1.4.1 Genetic factor 
It has been shown that genetic factors play a prominent role in susceptibility to 
MS. Adoption-study results reported that adoptive relatives, although raised from 
infancy with the MS patient, were no more likely to develop MS than expected for the 
general population. This data showed that the familiar aggregation of MS is related to 
genetic sharing rather than to shared family environment (Dyment et al., 2004). 
Confirmation of genetic predisposition comes primary from twin and sibling studies 
(Keegan and Noseworthy, 2002). Several twin studies have been done in MS. It has 
been shown that the concordance rate for MS in monozygotic twins is 25–30 %, in 
contrast to 3–5 % concordance between dizygotic twins and non-siblings (Sadovnick 
et al., 1996). MS risk is higher in offspring from both parents with MS than that of 
offspring with only one parent with MS (Dyment et al., 2004).  
 
The major histocompatibilty complex (MHC) in humans “human leukocyte 
antigen” (HLA) is unambiguously associated with MS (Dyment et al., 2004). There 
are over 200 genes within 4-5 megabase of the MHC. Many of these play an 
important role in the development, maturation, and composition of the T cell 
repertoire as well as in immunological processes. The HLA proteins are necessary for 
adaptive immunity because T cells are recognizing antigens only as peptides 
presented from antigen-presenting cells (APCs) such as astroglia, microglia, and 
macrophages in CNS. Whereas, HLA class I molecules present peptides to CD8+ T 
cells, antigens complexed with HLA class II molecules such as HLA-DR are 
recognized by CD4+ T helper lymphocytes.  
HLA-DR2 haplotype with the MHC on short arm of chromosome 6 is the 
strongest genetic effect identified in MS, and has been consistently demonstrated in 
family and case-control studies (Olerup and Hillert, 1991). MS patients from Sweden, 
Norway, Great Britain, Germany, Mexico, Canada, and Australia show mostly the 
haplotype DRB1*1501-DQA1*0102-DQB1*0602. In contrast, the MS patients from 
Asia are associated with the allele HLA-DRB1*0802. However the mechanism by 
which the MHC affects the MS is still unknown (Haines et al., 2002). 
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1.4.2 Infectious agent  
Association of viral and bacterial agents with MS has been reported but none 
of the associations are conclusive. The role of human herpes virus-6 (HHV-6) variant 
A in MS is supported by its higher neurotropism, increased lymphoproliferative 
response against variant A in MS patients (Soldan et al., 2000), and its 
deoxyribonucleic acid (DNA) presence in cerebrospinal fluid (CSF) from MS 
patients. Epstein-Barr virus (EBV) is also linked to MS as it has been reported that 
anti-EBV antibodies are elevated in MS patients compared with healthy individuals 
(Wandinger et al., 2000). It was also reported that the risk of MS is close to zero 
among individuals who are not infected with EBV, intermediate among individuals 
infected with EBV in early childhood, and highest among individual infected with 
EBV in adolescence or later in life (Thacker et al., 2006). 
Among bacteria, Chlamydia pneuemoniae (Cpn) has been implicated in MS. 
One study reported the presence of Cpn in the CSF of a large percentage of MS 
patients compared with healthy individuals (Sriram et al., 1999). Other studies failed 
to report an association between Cpn and MS (Pucci et al., 2000). 
Two main mechanisms have been proposed to explain how infectious agents 
induce MS (Sospedra and Martin, 2005): 
 
(a) Molecular mimicry: This involves activation of autoreactive T cells by cross 
reactivity between self and foreign antigens e.g. it has been reported that there is 
sequence homology between MBP and viruses. 
 
(b) Bystander activation: In this mechanism, autoreactive T cells are activated because 
of nonspecific inflammatory events that occur during infection. 
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1.4.3 Immune factor 
In principle, all of the immunocompetent cells are believed to participate in 
the pathogenesis of MS: APCs, T helper (CD4+,Th) cells, and effector cells like 
antibody-producing B lymphocytes and CD8+ cytotoxic T cells (Figure 2, page 17). 
Genetic and environmental factors may facilitate the increased movement of 
autoreactive Th cells from the systemic circulation into the CNS through disruption of 
blood-brain barrier. In the CNS, local factors may upregulate the expression of 
endothelial adhesion molecules such as intracellular adhesion molecule-1 (ICAM-1), 
vascular-cell adhesion molecule-1 (VCAM-1), and E-selectin, which further facilitate 
the entry of T cells into the CNS (Noseworthy et al., 2000). Th cells penetration from 
the circulation into the brain parenchyma is enhanced by increased activity of matrix 
metalloproteinase responsible for the breakdown of extracellular matrix material 
(Keegan and Noseworthy, 2002). 
Th cells are specifically activated in CNS by binding of putative MS antigens 
such as peptides from MBP, myelin oligogodendrocyte glycoprotein (MOG), 
proteolipid protein, αβ crystalline, phosphodiesterase and S-100 protein. T cell 
receptor (TCR) on Th cells recognize these antigens when these are associated with   
class II MHC molecules on APCs such as astrocytes, microglia, and macrophages 
(Noseworthy et al., 2000). Then interaction between the co-stimulatory molecules 
such as CD28 on Th and the proteins B7.1 or B7.2 on APCs further activates these 
cells. After these interactions, Th cell allow itself to proliferate. It achieves by 
releasing a potent T cell growth factor called interleukin (IL)-2. Activated Th cell also 
produce the alpha subunit of the IL-2 receptor (CD25 or IL-2Rα) enabling a fully 
functional receptor that can bind with IL-2, which in turn activates the T cell 
proliferation pathways. Th lymphocytes proliferate and can develop under appropriate 
conditions in cells secreting a relatively proinflammatory cytokine repertoire showing 
a type 1 helper T (Th1) pattern [tumor necrosis factor (TNF)-α, interferon (IFN)-γ, 
interleukin (IL)-12]. This Th1 cytokine repertoire leads to immune-mediated injury to 
myelin and oligodendrocytes. Alternatively, Th lymphocytes can differentiate in type 
2 helper T (Th2) cells secreting transforming growth factor (TGF-β), IL-4 and IL-10. 
Th2 cells may send anti-inflammatory signals to the activated APCs and stimulate 
pathologic or repair-enhancing antibody-producing B cells. CD8+ T cells may directly 
damage the oligodendrocyte and myelin. 
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It has been shown that MBP-reactive T cells are present in the T cell repertoire 
of both, MS patients and healthy individuals (Lunemann et al., 2004). This brings into 
question, why MS patients but not healthy individuals develop inflammatory tissue 
damage. Two explanations for this discrepancy have been assumed; (1) a higher 
frequency of MBP reactive T cells in MS patients compared with healthy individuals, 
and (2) a different pattern of peptide recognition by T cells. The evaluation of the 
precursor frequency of MBP-reactive T cells (Hong et al., 2004) as well as the 
analyses of antigen presentation and peptide specificity have been inconclusive 
(Davies et al., 2005). Therefore, the control of autoreactive T cells may be different in 
healthy individuals and MS patients.  
Disruption of blood-brain barrier may also result in the entry of autoreactive B 
cells, autoantibodies, and the complement factor into the CNS (Figure 2, page 17). 
Within CNS, autoreactive B cells may be activated by Th cells in association with 
antigen and differentiate into antibody-secreting plasma cells. Antibodies against 
antigens which are located on the surface of the myelin sheath or oligodendrocyte can 
cause demyelination. These antibodies may gain access to the CNS through disruption 
of the blood-brain barrier as a consequence of a T-cell initiated inflammatory 
response (Noseworthy et al., 2000). 
Autoantibodies detection against myelin antigens in the serum of MS patients 
has been elusive. This difficulty may in part be related to a tendency to form immune 
complexes which hampers detection (Dasgupta et al., 1983). Some studies have 
reported the elevated level of anti-MBP antibodies in MS compared with healthy 
individuals (Chamczuk et al., 2002; Reindl et al., 1999; Terryberry et al., 1998) 
whereas in some studies they are not detected (Colombo et al., 1997; Olsson et al., 
1990). MOG is also an important target antigen in MS and anti-MOG antibodies have 
been also reported (Reindl et al., 1999). Antibody-mediated effector mechanisms may 
cause damage by opsonization of autoimmune target. This aids macrophages-
mediated phagocytosis and by activation of the complement membrane attack 
complex, which may open pores in myelin membranes (Keegan and Noseworthy, 
2002).  
Multiple mechanisms of immune-mediated injury of myelin have been 
postulated; cytokine mediated injury of oligodendrocyte, digestion of surface myelin 
antigens by macrophages including binding of antibodies against myelin and 
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oligodendrocyte, complement mediated injury and direct injury of oligodendrocytes 
by CD4+ and CD8+ T cells (Figure 2, page 17). 
 
Figure 2    Possible mechanisms of injury and repair in multiple sclerosis. 
    This figure is adapted from Noseworthy et al. (2000). 
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Figure 3 extends the working hypothesis by the inclusion of “molecular mimicry” 
and regulatory T cells. 
 
 
Figure 3   Working hypothesis as to the cause of multiple sclerosis.  
(I) In a genetically susceptible host, common microbes activate antigen 
presenting cells (APCs) through molecules recognized by toll like 
receptors and protein sequences cross-reactive with self antigens 
recognized by major histocompatibility complex (MHC) class II 
molecules. This can be the minimum requirement for inducing multiple 
sclerosis (MS). (II) Loss of immuneregulation, such as loss of suppressive 
function of regulatory T cells in MS patients, allows further pathologic 
activation of autoreactive T cells. (III) Activated myelin reactive T cells 
migrate into central nervous system (CNS) and recognize antigen 
presented by microglia, local APCs. This results in secretion of type 1 
helper T (Th1) cytokines which initiate an inflammatory cascade. (IV) 
Naturally occurring mechanisms may exist which regulate autoimmune 
responses. This includes the induction of autoreactive type 2 helper T 
(interleukin-4, interleukin-5, interleukin-13), type 3 helper T (transforming 
growth factor-β), or T regulatory type 1 (Tr1, Interleukin-10) cytokines-
secreting T cells that migrate to CNS and downregulate (red arrow) 
inflammatory Th1 autoreactive T cells (green arrow). This figure is 
adapted from Hafler (2004). 
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1.5 Regulatory T cells 
Several subsets of regulatory T cells have been described. Inducible regulatory 
T cells such as T regulatory type 1 (TR1) or T helper type 3 (TH3) can develop from 
conventional Th cells (Beissert et al., 2006; Jonuleit and Schmitt, 2003). 
Another subset has been described as natural regulatory T cells (Treg) which is 
our focus of study. Treg are CD4+ cells which further express the IL-2α chain (CD25). 
These cells have been the object of intense study because their function appears to be 
important in maintaining self tolerance. 
Recently, thymocytes and peripheral blood T cells with the phenotype 
CD8+CD25+ as well as forkhead box P3 (FOXP3) expression has been described 
(Cosmi et al., 2003; Jarvis et al., 2005). These cells also share regulatory function.  
 
1.5.1  Natural regulatory T cells (Treg): An introduction 
 Treg have been first described in mice in 1995 (Sakaguchi et al., 1995). 
Sakaguchi et al. (1995) removed CD25 expressing cells from the splenic CD4+ cell 
population obtained from healthy BALB/c mice and injected these cells into athymic 
BALB/c mice; this results in the development of autoimmune gastritis. Addition of 
purified CD4+CD25+ cells to CD4+CD25- cells at the time of injection protected 
against the disease. Afterwards, other studies have also shown that co-transfer of Treg 
with CD4+CD25- prevents the development of experimentally induced autoimmune 
diseases such as colitis, insulin dependent autoimmune diabetes and thyroiditis 
(Powrie et al., 1997; Read et al., 2000; Salomon et al., 2000). Later, the existence of 
Treg has also been reported in human peripheral blood (Jonuleit et al., 2001) and 
thymus (Stephens et al., 2001).  
 
1.5.1.1 Molecular markers of Treg  
 A significant advancement in more precisely defining the Treg population 
occurred when the forkhead box P3 (FOXP3) transcription factor has been identified 
as being necessary for Treg development (Banham et al., 2006; Ziegler, 2007). In 
contrast to stable expression of FOXP3, other thymocytes, T cells, B cells, natural 
killer T cells do not express FOXP3 (Sakaguchi, 2005). This indicates that FOXP3 
expression is highly specific for Treg.   
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 Genetic mutations in the FoxP3 gene have been identified in both human and 
mice, and results in fatal autoimmune diseases. Human with mutations in FoxP3 gene 
suffer from a severe and rapidly fatal autoimmune disorder known as immune 
dysfunction, polyendrocrinopathy, enteropathy, X-linked inheritance (IPEX) 
syndrome. An analogous disease also occurs in mice, known as ‘scurfy’ (Le and 
Chao, 2007). 
FOXP3 suppresses IL-2 production and, thus abrogate the proliferation of Treg. 
In contrast FOXP3 upregulates the expression of other Treg associated molecules such 
as CD25, cytotoxic T lymphocyte-associated antigen (CTLA)-4 and glucocorticoid-
inducible tumor necrosis factor receptor (GITR) (Sakaguchi, 2005). Ectopic 
expression of FOXP3 in CD4+CD25- naïve T cell by retroviral gene transfer can 
convert them to phenotypically and functional Treg.  Thus, FoxP3 seems to be a 
‘master control gene’ for the development and function Treg (Figure 4, page 21). 
In addition to CD25 and FOXP3, other molecules are also expressed in higher 
density on cell surface of Treg such as IL-2R β-chain (CD122), CD44, CD54, GITR, 
neuropillin-1, and lymphocyte activation gene 3 (LAG-3) (Suri-Payer and Fritzsching, 
2006). CTLA-4 and CD152 are also constitutively expressed in the cytoplasm of Treg. 
It has been also described that these cells are HLA-DR positive (Baecher-Allan et al., 
2001). Recently, it has been shown that Treg are also described by the lower surface 
expression of CD127 marker (Hartigan-O'Connor et al., 2007). 
CD25 expression of Treg from mouse and human is different. In mouse, Treg are 
seen as a distinct population of cells that is easily distinguished from CD4+CD25-. In 
contrast, human CD4+ T cell exhibit a continuous and primary low expression of 
CD25 (Baecher-Allan et al., 2001; Baecher-Allan et al., 2004).  
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Figure 4  Control of regulatory T cell-associated molecules in natural regulatory T 
cells. 
Forkhead box P3 (FoxP3) seems to control genes which encode natural 
regulatory T cells-associated molecules such as CD25, glucocorticoid-
inducible tumor necrosis factor receptor (GITR) and cytotoxic T 
lymphocyte-associated antigen-4 (CTLA-4). T cell receptor signals and 
also binding of interleukin-2 to interleukin-2 receptor enhance CD25 
expression. This figure is adapted from Sakaguchi (2005). 
 
 
 
1.5.1.2 Function of Treg  
Upon activation of Treg via their TCR, the main function of these cells is to 
suppress the proliferation of effector cells such as Th, CD8+ cells, B cells, NK cells as 
well as APCs. Accumulating evidences suggest that Treg are actively engaged in 
variety of physiological and pathological immune responses. These cells not only 
prevent the development of autoimmune diseases but are also responsible for the 
induction of immunological tolerance to non-self antigens (such as transplantation 
tolerance), negative control of aberrant immune responses (such as allergy and 
immunopathology), and enhancement of host defense (such as tumor immunity and 
microbial immunity) (Sakaguchi, 2005) (Figure 5, page 22).  
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Figure 5  Linkage of central and peripheral tolerance by thymic production of 
natural regulatory T cells that contributes self tolerance.  
A decrease in natural regulatory T cells (Treg) number or impairment in 
suppressive function may result in autoimmunity, tumor immunity, 
microbial immunity and allergy. On the other hand, increase in Treg 
number or augmentation of their suppressive activity may result in 
transplantation tolerance and maintain feto-maternal tolerance. Treg may 
control effector T cells (Teff) either directly or indirectly through antigen 
presenting cells. This figure is adapted from Sakaguchi( 2005). 
 
1.5.1.3 Mechanisms of suppression of effector T cells proliferation by Treg  
The mechanism of suppressive activity of Treg is less understood. In vitro 
studies have shown that suppression of effector T cells proliferation requires direct 
cell contact between Treg and the target effector T cells and is cytokine independent 
(Le and Chao, 2007; Piccirillo et al., 2002; Suri-Payer and Cantor, 2001; Takahashi et 
al., 1998). APCs are also not essential as suppression of effector T cell proliferation 
occurs in APC-free cultures (von Boehmer, 2005). It appears that Treg must be 
activated in order to perform suppressive function, and has been shown by two 
separate studies in which fixed, bead isolated Treg could suppress effector T cell 
proliferation, only if Treg is preactivated before the fixation (Baecher-Allan et al., 
2004). 
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Cytokines involvement in Treg suppression is controversial. It has been shown 
that Treg produce IL-10 in vivo, and it has been established that certain form of 
autoimmunity such as colitis can be suppressed by Treg and require IL-10.  Whereas, 
other studies have reported that autoimmune disease can be suppressed independently 
of IL-10 (von Boehmer, 2005). Involvement of transforming growth factor (TGF)-β is 
difficult to say as some studies have reported that Treg isolated from the blood shows 
no effect on the suppression of effector T cells proliferation by blocking TGF-β while 
others have reported that neutralizing TGF-β reduces the suppression (Annunziato et 
al., 2002; Nakamura et al., 2004). 
The estimation of the proliferation of mitogen-activated T lymphocytes is a 
common measure for T cell reactivity. We (Mueller et al., 2003) and Bo et al. (2001) 
have found that impaired proliferative responses to mitogens may be due to a high 
local production of tumor necrosis factor (TNF)-α . Recently, it has been shown that 
anti-TNF-α therapy in rheumatoid arthritis generates naïve population of Treg, which 
compensates for the defective Treg (Nadkarni et al., 2007).  
Recent, in vitro studies on immunosuppression have suggested the function of 
CD80 and CD86 ligands that are present on activated Th cells. These molecules are 
essential in Treg mediated suppression as it is found that their absence results in 
marked reduced susceptibility to suppression by Treg compared with wild-type of 
effector T cells (von Boehmer, 2005). This hypothesis of mechanism of suppression 
of effector T cells proliferation is described in Figure 6, page 24. 
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Figure 6 Cytotoxic T lymphocyte-associated antigen 4 and CD80 and/or CD86 in 
suppression of effector T cells proliferation by natural regulatory T cells. 
(A) Natural regulatory T (T suppressors) and T effector cells meet at an 
antigen presenting cells (APCs) and facilitate binding of cytotoxic T 
lymphocyte-associated antigen-4 (CTLA-4) on T suppressors to CD80 
and/or CD86 (CD80/CD86) on activated effectors. ‘Outside signaling’ 
by CD80 and/or CD86 then prevent the activation of effectors. 
(B) T suppressors could activate indolamine 2, 3 dioxygenase (IDO) when 
CTLA-4 on T suppressors binds to CD80 and/or CD86 on APCs. The 
IDO dependent metabolism of tryptophan would prevent activation of 
T effectors cells. 
(C) In the absence of T suppressors, mutual binding of CTLA-4 and CD80 
and/or CD86 by effector T cells cause interference with their further 
activation through cell-autonomous inhibitory signals by CTLA-4. 
This figure is adapted from von Boehmer (2005) with required 
modification. 
A 
B 
C 
 25
1.5.1.4 Number and function of Treg in MS 
MS is believed to be an autoimmune disease so it was interesting to study Treg 
function and cell numbers in this disease. 
Only a few studies have been done on Treg number with different results using 
different definitions for Treg. It has been reported that compared with healthy 
individuals, the number of circulating Treg was decreased (Khoury et al., 2000) or 
unchanged (Haas et al., 2005; Putheti et al., 2004; Venken et al., 2006; Viglietta et al., 
2004) in MS patients. 
Recently, three reports have been published regarding Treg function. In two of 
the studies CD25high expressing cells are used. According to Viglietta et al. (2004) 
mitogen-stimulated lymphocytes of MS patients have showed an impaired 
suppressive function of Treg. Moreover, reduced antigen-specific suppression are 
described in myelin oligodendrocyte glycoprotein (MOG) stimulated lymphocytes 
(Haas et al., 2005). The third study used the same reagents as us and has found also a 
reduced Treg function toward mitogen-induced proliferation in RR MS patients 
compared with healthy individuals (Venken et al., 2006). But no studies have been 
performed using the most abundant protein in CNS, the MBP.  
 
1.6 Therapy  
In view of the likely autoimmune pathogenesis of MS, the therapy of this 
disease is based on the use of agents influencing the immune system, e.g. interferon 
(IFN) as cytokines, an antigenic substance resembling MBP in the amino acid 
composition (glatiramer acetate), antagonists of adhesion [anti-very late antigen-4 
(VLA-4) antibody], and agents which suppress proliferation of immune cells. 
There are six “Food and Drug Administration” (FDA) approved treatments for 
relapsing remitting MS: two IFN-β1a agents (Avonex® and Rebif®), one IFN-β1b 
(Betaseron®), glatiramer acetate (Copaxone®), anti-VLA-4 monoclonal antibody 
(Tysabri®) and mitoxantrone (Novantrone®) for progressing advanced cases (Hafler et 
al., 2005). Mitoxantrone (MX) and other anti-proliferative agent cyclophosphamide 
are prescribed for secondary progressive MS.  
Interferon-1β is naturally occurring cytokine. Although, its exact mode of 
action is not known but it has been found to suppress T cell proliferation, reduce T 
cell migration from the systemic circulation into the CNS, and alter Th1 to Th2 
response.  
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Copaxone is a synthetic peptide of four amino acids (L-glutamic acid, L-
lysine, L-alanine, and L-tyrosine). Its structure resembles MBP. It is an 
immunomodulator that appears to block myelin-specific autoimmune responses and 
also alters the immune response from Th1 to Th2 (Keegan and Noseworthy, 2002). 
Mitoxantrone (MX) is an anthracenedione derivative of doxyrubicin which is 
highly effective in the treatment of progressive MS (Hartung et al., 2002). It reduces 
both attack and progression rates and has been approved for the patients with 
secondary progressive and worsening forms of MS (Jain, 2000; Neuhaus et al., 2006). 
MX is a DNA-intercalating agent which interacts with topoisomerase-2, and inhibits 
DNA and RNA synthesis (Smith, 1983). Furthermore, MX acts as an 
immunosuppressant targeting proliferating immune cells. It suppresses the 
proliferation of T lymphocytes, B cells, and macrophages (Fidler et al., 1986a; Fidler 
et al., 1986b; Wang et al., 1986). It also inhibits B cell function and antibody 
production (Fidler et al., 1986a). Despite its widespread use in the treatment of MS, 
the immunological effects of MX are not fully understood. Ex vivo analyses in MS 
patients have revealed that MX induces suppression of mononuclear cell proliferative 
responses and alterations of lymphocyte subsets (Chan et al., 2005; Gbadamosi et al., 
2003). These studies mainly examined acute or short-term effects of MX. 
Treatment with MX and cyclophosphamide are effective but associated with 
significant toxicity. Moreover, all therapies have a limited effect. Thus there is a need 
to develop new therapies with low toxicity and higher efficiency. An ideal therapy 
could be to prevent the initiation of such attacks and reduce progression by correcting 
the dysregulated immune system. 
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1.7 Aim of the study 
Multiple sclerosis (MS) is an inflammatory autoimmune disorder of the central 
nervous system which is thought to result from aberrant T cell immune response to 
self antigens e.g. myelin basic protein (MBP). Active suppression by natural 
CD4+CD25+ regulatory T cells (Treg) plays a key role in the control of self-antigen-
reactive cells and in the induction of peripheral tolerance in vivo.  
Only a few publications have been reported describing the number and 
function of Treg in MS. In these reports, Treg are defined mainly by CD25high 
expression. These cells are only available after time and cost-consuming use of a 
fluorescence-activated cell sorter. With the introduction of reagents using magnetic 
separation of CD4+ lymphocytes in CD25+ and CD25- cells it is now possible to get in 
a relatively short time, large number of Treg for functional studies. Therefore, we used 
this separation technique for studying Treg (mixture of CD25high and CD25intermediate) 
regarding function in an in vitro proliferation assay using most abundant protein in 
CNS, MBP, as an antigen. Moreover, we estimated number of Treg as well as 
leukocytes and their subpopulations in MS patients and healthy individuals. FOXP3 
and HLA-DR are other markers for Treg. To characterize our Treg, it was also 
important to see the expression of FOXP3 and HLA-DR on these cells. 
In order to elucidate the possible mechanisms for suppressive activity of Treg, 
we also looked for the role of cytokines e.g. TNF-α. 
Antibody production is the last step in the immune response and MS seems to 
be associated with increased concentration of anti MBP antibodies, we also measured 
these autoantibodies in MS. 
 Mitoxantrone (MX) is a potent immunosuppressive agent in the treatment of 
active relapsing remitting and secondary progressive MS. Therefore, our next aim of 
study was to analyze the effect of this drug on number and function of Treg.  
 28
2 Materials and methods  
 
2.1  Patients and healthy individuals 
The study was approved by the local ethics committee. All MS patients and 
blood donors (healthy individuals, Institut fuer Transfusionsmedizin, 
Universitaetsklinikum Essen) gave written informed consent prior to the study. 
During the time of the study, we included all patients at our MS center of the 
Department of Neurology, University hospital, University of Duisburg-Essen, who 
fulfilled our predefined inclusion criteria: (i) patients had to suffer from clinical 
definite relapsing remitting or secondary progressive MS according to the McDonald 
criteria (McDonald et al., 2001), (ii) they had to be untreated for at least 6 months, 
(iii) they had to be relapse free for at least 8 weeks and (iv) they had not received 
treatment for at least 8 weeks. 
 
Forty millilitre heparinized blood, 5 ml ethylene diamine tetraacetic acid 
(EDTA) blood and 10 ml blood without anticoagulants for getting serum was 
collected by venipuncture in the morning from each individual.  
For enumeration and function of Treg in MS patients and healthy individuals, 
35 patients (13 males and 22 females; RR = 25 and SP = 10) and 34 healthy (17 
males, 17 females) were enrolled in our study. The mean and standard deviation 
(mean+SD) was calculated for patients age (40±10 years, range 20-69 years), disease 
duration (7.4±5.9 years, range 0.5-25 years) and expanded disability status score 
(EDSS; 3.7±2, range 1.0-7.5). The age (mean+SD) of the healthy individuals was 
40±12 years, range 21-62 years. There was no significant difference for age and sex 
between MS patients and healthy individuals. 
For MX follow up study, twenty MS patients (5 males and 15 females; RR = 
6, SP = 12 and PP = 2) were included. Their age was 41±8 years (range 24-57 years), 
the disease duration was 10±5 years (range 3-19 years) and their EDSS values 5.6±1.3 
(range 3-8). Eleven patients from this group were already included for testing of 
enumeration and function of Treg. All patients received MX de novo. MX was given at 
a standardized dose of 10 mg/m2 in all patients. Intravenous application was 
performed after antiemetic treatment during one hour. Blood was always collected 
before treatment and at intervals of 3 months up to one year immediately before 
infusion of MX to investigate long-term effects of the applications.  
 29
For antibody analysis, 39 MS patients (11 males and 28 females; RR = 25, SP 
= 14) and 39 healthy individuals (15 males and 24 females) were enrolled. Thirty two 
MS patients from this group were included for testing of enumeration and function of 
Treg and rest 7 were included for MX follow up study. The age of the healthy 
individuals was 42±8 years, range 24-60 years. Only four healthy individuals from 
this group were included for testing of enumeration and function of Treg. There was no 
significant difference for age and sex between MS patients and healthy individuals. 
 
2.2  Chemicals and reagents 
All the chemicals and reagents used throughout this work were purchased 
from the different companies as given in Table 1. If not otherwise stated the 
chemicals and reagents were bought in Germany. 
Table 1    List of Chemicals and reagents  
 
Chemicals/Reagents Company 
Bovine seum albumin (BSA) Merck , Darmstadt  
Carbonate/bicarbonate buffer capsule  Sigma-Aldrich,steinheim 
Ficoll-Paque plus  Amersham Biosciences,  
 Uppsala, Sweden 
Foetal Calf Serum (FCS) Biochrom, Berlin  
 7.25 % Hydro chloric acid (HCl) Braun Melsungen, Melsungen 
Heparin (Liquemin N25000) Roche, Grenzach-wyhlen 
L-glutamine Sigma-Aldrich 
Myelin Basic Protein (MBP) Acris Antibodies, Hiddenhausen 
Penicilin Gibco, Karlsruhe 
Phosphate buffered  saline (PBS) Gibco 
Pokeweed Mitogen (PWM) Sigma-Aldrich 
Rosewell Park Memorial Institute (RPMI)  
1640 medium Gibco 
ß-Mercaptoethanol Sigma-Aldrich 
Streptomycin Gibco 
Trypan blue Sigma-Aldrich 
Tween 20 Merck Schuchardt, Hohenbrunn 
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2.3 Antibodies for flow cytometry 
All antibodies as given in Table 2.a and b were purchased from Becton 
Dickinson (BD) Biosciences, Heidelberg, Germany, except tumor necrosis factor 
(TNF)-α antibody conjugated with fluorescein isothiocyanate (FITC) which was 
purchased from BD Pharmingen, Heidelberg, Germany. 
 
Table 2.a   List of four and three color antibodies 
 
FITC/PE/PerCP/ 
PerCPCy5.5*/ 
Antibody Clone Order.Nr. Amount/tube 
MultiTEST 
CD3/8/45/4 SK7/SK1/2D1/SK3 342417 20 µl 
MultiTEST 
CD3/16+56/45/19 
SK7/B73.1/NCAM16.2/
2D1/SJ25C1 342416 20 µl 
Oncomark 
CD4/25/3 SK3/2A3/SK7 341134 20 µl 
Tritest CD4/8/3 SK3/SK1/SK7 342414 20 µl 
  
* Fluorescein isothiocyanate (FITC)/ phycoerythin (PE)/ peridinin chlorophyll protein 
(PerCP)/ peridinin chlorophyll protein cyanine 5.5 (PerCPCy5.5) 
 
Table 2.b   List of single color antibodies 
 
Antibody/IgG class Clone Order Nr. Amount/tube
CD14 APC#/IgG2b MoP9 345787 2 µl 
CD8 APC/IgG1 SK1 345775 2 µl 
HLA-DR APC /IgG2a L243 347403  1 µl 
CD4PE/IgG1 SK3 345766 10 µl 
CD3PerCP/IgG1 SK7 345769 10 µl 
TNF-αFITC/IgG1 MAb11 554512 5 µl 
MouseIgG1FITC X40 345815 5 µl 
 
# Allophycocyanin (APC) 
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2.4 Culture medium 
RPMI 1640 medium was used for all cultures containing 25 mM HEPES, 
supplemented with 2 mM L-glutamine, 200 U/ml penicillin and 200 µg/ml 
streptomycin. The medium was further supplemented with 10 % heat–inactivated 
pooled human serum (Institut fuer Transfusionsmedizin, Universitaetsklinikum 
Essen).  
 
2.5 Myelin basic protein (MBP) reconstitution 
   One milligram of myelin basic protein (MBP) was reconstituted in 10 mM 
HCl. MBP powder was first dissolved in 100 µl of HCl (7.25 % HCl was added in 2 
ml sterile water) and then diluted with 900 µl PBS. Final concentration of MBP was 1 
mg/ml, which was used for stimulation. 
 
2.6  Isolation of Treg and CD4+CD25 – cells  
2.6.1 Principle 
Isolation kit from CellSystems Biotechnologie (St. Katharinen, Germany) was 
used which involves RosetteSep and EasySep to isolate Treg and CD4+CD25- cells. 
RosetteSep is a rapid and easy cell separation procedure for the isolation of highly 
purified cells directly from whole blood. Utilizing antibody-based tetrameric antibody 
complex (TAC) technology, RosetteSep turns a simple buoyant density centrifugation 
into a specific, antibody-mediated cell enrichment system. In this procedure, sample is 
incubated with the antibody-based enrichment cocktail at room temperature (RT), 
followed by standard buoyant density separation. The antibody-based enrichment 
cocktail crosslinks unwanted cells (CD8+, CD16+, CD19+, CD36+, CD56+, and 
CD66b+) to multiple red blood cells (RBCs) to pellet them along with free red blood 
cells by density centrifugation (negative selection for CD4+). This increases the 
density of the unwanted cells and the pellet down along with the free RBCs when 
centrifuged over a buoyant density medium such as Ficoll-Paque. Desired cells are 
not labelled with antibody and are easily collected as a highly enriched population at 
the interface between plasma and density medium. 
EasySep involves labelling of target cells with dextran-coated magnetic 
nanoparticles using bispecific TAC. These complexes recognize both dextran and the 
target cell surface antigen (Figure 7, page 32). The small size of the magnetic dextran 
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iron particles allows for efficient binding to the TAC-labelled cells. These magnetic 
labelled cells are then separated from unlabeled cells. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 Magnetic isolation of natural regulatory T (CD4+CD25+) cells.  
    This figure is adapted from StemCell technologies (www.stemcell.com). 
 
2.6.2 Procedure  
Thirty millilitre of heparinized venous blood samples were used for isolation 
of Treg and CD4+CD25- cells. Forty microlitre “RosetteSepTM CD4+ cell enrichment 
cocktail” (CellSystems Biotechnologie) was added per millilitre of blood and 
incubated for 15 minutes (min). After incubation, blood samples were diluted with an 
equal volume of PBS enriched with 2 % FCS. Diluted blood samples were layered 
onto 15 ml Ficoll-PaqueTM plus density medium and centrifuged [1,200xg, 20 min at 
room temperature (RT)]. Cells removed from the density medium/plasma interface 
contained enriched CD4+ cells. They were washed 2 times with PBS plus 2 % FCS 
(400xg, 10 min at RT). After washing, cells were resuspended at 1 x 107 cells per 100 
µl PBS plus 2 % FCS and incubated with 100 µl of “EasySepTM CD25 positive 
Selection Cocktail” per ml of sample for 15 min. CD25+ cells were isolated by adding 
50 µl of EasySepTM SA Magnetic Nanoparticles (CellSystems Biotechnologie) per 
millilitre of sample. After incubation for 10 min, 2.1 ml PBS plus 2 % FCS was 
added. The tube was placed in the EasySep magnet (CellSystems Biotechnologie) for 
5 min. Thereafter, the supernatant containing the CD4+CD25- cells was poured into 
another tube by inverting magnet and tube in one continuous motion. This magnetic 
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step was repeated two times more to get pure Treg and all supernatants were combined 
to receive the CD4+CD25- cells. These CD4+CD25- cells were centrifuged (400xg, 5 
min at RT) and resuspended in 1 ml RPMI 1640 medium. The tube containing Treg 
was removed from the magnet and the cells were also resuspended in 1 ml RPMI 
1640 medium.  
For FOXP3 expression, Isolated Treg and CD4+CD25- cells were first snap 
frozen in liquid nitrogen and then finally stored in -80°C until use. 
 
2.7 Isolation of peripheral blood mononuclear cells (PBMCs) 
PBMCs were isolated from seven millilitre of heparinized whole blood by 
Ficoll-PaqueTM plus density gradients. Blood samples were diluted with an equal 
volume of phosphate buffered saline and then diluted blood samples were layered 
onto 15 ml Ficoll-PaqueTM plus density medium and centrifuged (400xg, 30 min at 
RT). PBMCs were removed from the density medium/plasma interface and were 
washed twice with PBS (400xg, 10 min at RT).  
 
2.8       Cell proliferation assays 
2.8.1 Optimization of the antigen concentration and cell numbers for our   
            proliferation assay  
 To optimise MBP concentrations, 1 x 105 PBMCs/well were stimulated with 
0.5, 1, 2, 4 and 8 µg MBP/well. 
For PBMCs cell number optimisation, 0.5 x 105, 1 x 105, 1.5 x 105, 2 x 105 and 
2.5 x 105 cells/well were stimulated with 4 µg/well of MBP. Isolated Treg and 
CD4+CD25- cell numbers were also optimised using different cell numbers. 2.5 x 103, 
5 x 103, 7.5 x 103 and 10 x 103 cells/well were added into 1 x 105 PBMCs and 
stimulated with 4 µg/well of MBP. 
 
2.8.2 Function of Treg 
To assess the functional activity of Treg, 1 x 105 PBMCs plus 1 x 104 
CD4+CD25- cells were cultured in absence (CD25NEG) or presence of 1 x 104 Treg 
(CD25MIX) in 230 µl RPMI 1640 in U-bottom wells (96-well plate; BD Labware, 
Heidelberg, Germany). We used CD4+CD25- cells in order to increase the number of 
MBP specific responder T cells. Furthermore, during isolation procedure, some cells 
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may get activated. Hence as a control, we added isolated CD4+CD25- cells in PBMCs. 
Then we estimated the effect of Treg on PBMCs plus CD4+CD25- cells. 
Cells (CD25NEG or CD25MIX) were cultured in 230 µl RPMI 1640 medium 
without any stimulation (autologous cultures) or stimulated with either 5 µg/well of 
MBP (antigen) or 1 µg/well of pokeweed mitogen (PWM, mitogen) in U-bottom wells. 
Cultures were set up as triplicates and incubated at 37°C in a humidified atmosphere 
with 5 % CO2.  
After 5 days of cultures, 1 µCi of 3H-thymidine (Amersham Buchler, 
Braunschweig, Germany) per well was added and incubated for further 16 hours. Using 
a multiple automatic sample harvester (Mach III Harvester96; Tomtec, Hamden, UK), 
cells were harvested on glass fiber paper and counted in scintillation fluid (Betaplate-
Scint; Wallac, Turku, Finland). 3H-thymidine incorporation was measured as counts per 
minute (cpm). The stimulation index (SI) was calculated by dividing the mean (cpm) of 
triplicate samples (MBP or PWM-induced proliferation) by the mean (cpm) of triplicate 
autologous cultures. The percentage of suppression of Treg (CD25MIX) was calculated 
by setting the SI values of CD25NEG cultures to 100 % proliferation. 
 
2.9 Counting of Cell numbers 
Isolated cells were counted using haemocytometer counting chamber. In brief, 
cells were diluted in ready trypan blue solution. Then the diluted suspension was 
introduced in this chamber which was covered with cover slip and counted under the 
microscope in all four corners. 
Cell numbers = (total cell counted/4) x dilution factor x 104 cell per ml. 
 
2.10 Flow cytometry 
2.10.1 Principle 
Flow cytometry uses the principle of light scattering, light excitation and 
emission of fluorochrome molecules for the measurement of characteristics of single 
cells. Cells suspended in sheath fluid that allows the cells to flow in a defined stream 
of single file pass under hydrodynamic pressure. The moving cell hits the focused 
beam of laser lights and the light is scattered in the forward direction (FSC, indicates 
size of the cell) and in the side direction (SSC, indicates contents and the granularity 
of the cell) with respect to the laser beam. The laser beam excites the dyes bound to 
the monoclonal antibodies marking the cells to fluorescence. A series of 
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photomultiplier tubes (PMTs) detectors collect these informations and converted into 
a form suitable for computer storage and subsequent analysis (Figure 8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8   Schematic diagram of flow cytometry. 
 
2.10.2  Procedure 
 Four color flow cytometry was used for enumeration of whole blood and 
different subpopulation of leukocytes.  
 
2.10.2.1 Surface staining 
  To stain cells of interest, first different antibodies were added. After addition 
of antibodies, 50 µl of whole blood or isolated cells were added and incubated for 15 
min at RT. Thereafter, 500 µl of BD FACS lysing solution (BD Biosciences) was 
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added, mixed and incubated for 15 min. Samples were measured in a FACSCalibur 
and analyzed utilizing CellQuest software (BD Biosciences). 
True count beads (BD, Heidelberg, Germany) containing MultiTEST 
CD3+FITC/CD8+PE/CD45+PerCP/CD4+APC and CD14+APC were used to count the 
absolute number of leukcocytes. Relative number of lymphocytes, T cells (CD3+) and 
their subpopulations (CD4+ and CD8+) were enumerated using MultiTEST 
CD3+FITC/CD8+PE/CD45+PerCP/CD4+APC and CD14+APC. To enumerate relative 
number of B lymphocytes cells, MultiTEST CD3+FITC/CD16++56+PE/ CD45+PerCP 
/CD19+APC were used. 
Relative number of CD25 expressing CD3+ cells in whole blood cells and 
purity of isolated CD4+,  Treg, and CD4+CD25- cells were measured using BD 
OncomarkTM CD4+FITC/CD25+PE/CD3+PerCP-Cy5.5 and CD8+APC. HLA-DR 
expression of CD3+ cells was measured in whole blood using Tritest CD4+ FITC/ 
CD8+ PE/CD3+ PerCP and HLA-DR+ APC. 
To analyze, B lymphocytes, CD3+ cells and their subpopulations, lymphocytes 
were gated. For analysis of CD25 and HLA-DR expressing CD3+ cells, CD3+ cells were 
gated. Three thousand events were acquired on gated cells. HLA-DR positivity was 
defined as described in Ditschkowski et al. (1999) The relative number of B and CD3+ 
lymphocytes are given as a percentage of lymphocytes. For relative number of T cells 
expressing CD4+, CD8+, CD25+ or HLA-DR+, percentage of CD3+ in whole blood was 
calculated. To obtain the absolute number of B cells, first lymphocytes number were 
calculated from relative lymphocyte number and leukocytes number. Then from 
lymphocytes number, absolute number of B cells was calculated using the relative B 
cell number.  
  
2.10.2.2 Intracellular staining 
  First cells were collected after 5 days of cultures and centrifuged (400xg, 5 
min at RT). Supernatant was discarded and 1 ml of 1 % BSA + PBS was added for 
washing (centrifuge at 400xg, 5 min at RT). After washing the cells were diluted in 1 
% BSA + PBS according to number of tube (100 µl per tube). For staining, 200 µl 
PBS was first added in each tube and then different antibodies (CD4+PE, CD3+PerCP 
and CD45+FITC/CD14+PE) were added. Then 100 µl cells were added in each tube 
and incubated for 15 min. After incubation, 1 ml of 1 % BSA + PBS were added for 
washing (centrifuge at 400xg, 5 min at RT). 
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 After washing, 200 µl BD cytofix + cytoperm (BD Biosciences) were added 
and incubated for 20 min at 4°C. Wash was repeated with 1 ml of 1 % BDPerm/Wash 
(BD Biosciences). 1 % BDPerm/Wash was prepared by diluting BDPerm/Wash in 
sterile water. 
Meanwhile antibodies were diluted as 5 µl antibody + 50 µl of 1 % 
BDPerm/Wash per tube. TNF-α FITC and Mouse IgG1 FITC (isotype control) were 
used for measurement of TNF-α expression. 
Fifty microlitre of diluted antibodies were added in each tube and incubated 
for 30 min at 4°C. After incubation, 1 ml of 1 % BDPerm/Wash was added for 
washing. After washing, stained cells were resuspended in 200 µl PBS and then were 
measured in a FACSCalibur and analyzed utilizing CellQuest software. 
 
2.11 Evaluation of FOXP3 expression  
2.11.1 Isolation of RNA 
Isolation of ribonucleic acid (RNA) from Treg or CD4+CD25- cells was 
performed using the RNeasy Kit (Qiagen, Hilden, Germany), including the optional 
DNase digest (RNase-free DNase set). Isolated cells stored at -80°C were flicked to 
loosen the pellets. This step and the following procedure were performed at RT. 
In RLT (company designed buffer) buffer, 1 % β-mercaptoethanol was added 
first and 600 µl of this RLT buffer was added to the cells and mixed it well by 
vortexing. Then lysate was pipetted directly into a QIAshredder spin column which 
was placed in a 2 ml collection tube and centrifuged (10,000xg, 2 min at RT). 600 µl 
of 70 % ethanol was added to the homogenized lysate and then 600 µl of the sample 
was pipetted into QIAamp spin column placed in a 2 ml collection tube and 
centrifuged (10,000xg, 15 sec at RT). The flow through was then discarded and rest 
600 µl of the sample was pipetted again into QIAamp spin column and centrifuged for 
15 sec at maximum speed. After discarding the flow through, 350 µl RWI buffer 
(company designed buffer) was added and centrifuged (10,000xg, 15 sec at RT). 
       Ten microlitre Dnase 1 stock solutions was added to 70 µl buffer RDD 
(company designed buffer) and this Dnase incubation mix (80 µl) was pipetted 
directly onto the RNeasy silica-gel membrane and left on it for 30 min. Thereafter, 
350 µl RWI buffer was again added and centrifuged (10,000xg, 15 sec at RT) and the 
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QIAamp spin column transferred into a 1 ml eppendorf tube and 30 µl of RNase free 
water was pipetted directly onto the QIAamp membrane and centrifuged (10,000xg, 1 
min at RT). Again 30 µl of RNase free water pipetted directly onto the QIAamp 
membrane and centrifuge (10,000xg, 1 min at RT). The eppendorf contained RNA in 
volume of 60 µl. 
 
2.11.2  cDNA synthesis from isolated RNA 
   Utilizing the Gold RNA PCR core kit (Applied Biosystems, Foster City, CA, 
USA), 150-600 ng of RNA were reverse transcribed in a total volume of 20 µl in a 
Gene-Amp PCR system 9700 (Applied Biosystems).  
 
The reaction mix for cDNA synthesis was as follows.  
5xRT (company designed buffer)    4 µl 
25 mM MgCl2       2 µl  
10 mM dNTP (Deoxyribonucleotide triphosphate)  2 µl 
RNase inhibitor              0.5 µl 
10 mM DTT (dithiothreitol)     2 µl 
Random Hexamer oligonucleotide            0.5 µl 
Reverse Transcriptase              0.3 µl    
              11.3 µl 
 
8.7 µl of RNA (150-600 ng) and water were added to make final volume of 20 µl. 
Conditions for reaction were as follows: 25°C for 10 min, 42°C for 15 min, 95°C for 5 
min, and 5°C for 5 min. 
 
2.11.3    Real time PCR to evaluate FOXP3 expression  
2.11.3.1 Principle 
  Real time polymerase chain reaction (PCR) is a method for quantitative 
detection of the initial amounts of DNA template in a sample. Most commonly used 
Real time PCR methods are TaqMan and SYBR Green methods, which utilize 
fluorescent-based DNA methodology.  
TaqMan methodology is based on the 5’ nuclease assay first described by 
Holland et al. (1991), which uses the 5’-3’ exonuclease activity of Taq DNA 
polymerase to cleave a dual-labeled probe annealed to a target sequence during PCR-
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amplification (Figure 9). The TaqMan probe contains both a fluorescent dye at the 5’-
end and a quencher dye at the 3’-end. The quencher can only quench the reporter 
fluorescence when the two dyes are close to each other which are only in case of an 
intact probe. Once amplification occurs, the probe is degraded by the 5’-3’ exonuclease 
activity of Taq DNA polymerase, and the fluorescence will be detected by a laser in 
integrated in the sequence detector (ABI 7000 Real-Time PCR system, Foster City, CA, 
USA). The PCR cycle number at which fluorescence reaches a threshold value of 10 
times the standard deviation of baseline emission is used for quantitative measurement. 
This cycle number is called the cycle threshold (Ct) and it is inversely proportional to 
the starting amount of the target cDNA. 
 
 
 
 
 
 
 
 
 
 
Figure 9      Mechanism of TaqMan method. 
         This figure is adapted from Takara Mirus Bio, Madison, Wisconsin       
                    (www.takarabiousa.com). 
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2.11.3.2 Procedure 
  The amount of FOXP3 and β-actin (ACTB; house keeping gene) message 
was quantified with an ABI 7000 Real time PCR system using TaqMan Gene 
Expression Assays (Assay IDs: Hs00203958_m1 for FOXP3, Hs99999903_m1 for 
ACTB; Applied Biosystems). Twenty five microlitre reaction mixtures containing 2.5 
µl cDNA were run in duplicates. 
The reaction mix was as follows:  
Assays   1.25 µl 
2xMix (PCR Mix) 12.5 µl 
 H20   8.75 µl 
cDNA              2.50 µl 
 
  ∆Ct values for FOXP3 were calculated taking the house keeping ACTB as 
standard gene. The difference in FOXP3 expression between Treg and CD4+CD25- 
cells was calculated as fold difference = 2 ∆∆Ct where ∆∆Ct = (∆Ct CD4+CD25-) - (∆Ct 
Treg). 
 
2.12 Enzyme linked immunosorbent assay (ELISA) to detect antibodies 
against MBP  
2.12.1  Principle 
Enzyme linked immunosorbent assay (ELISA) is a commonly used 
immunoassay which combines the specificity of antibodies with the sensitivity of 
simple enzyme assay, by using antibodies or antigens coupled to an easily assayed 
enzyme. ELISA can be used to detect the presence of antigens that are recognized by 
an antibody or to detect antibodies that are recognized by an antibody. 
To quantitate the human antibodies directed against MBP, we used a modified 
method described by Chamczuk et al. (2002). The standard curve was obtained using 
a monoclonal antibody (first antibody) from the mouse directed against human MBP. 
This monoclonal antibody was marked by a second antibody (coupled with an 
enzyme) directed against the immunoglobulin (Ig) G class of the first antibody.  
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The human antibodies were detected in the same indirect way that means by a 
second enzyme coupled antibody directed against the human IgG. 
Our ELISA is a five-step procedure (Figure10)  
a) Coating of microtiter plate wells with antigen,  
b) blocking of all unbound sites to prevent false positive results,  
c) addition of serum sample containing antibodies to well,  
d) addition of secondary antibody conjugated to enzyme and 
e) reaction of a substrate with the enzyme to produce a colored product. 
 
 
 
 
Figure 10   Schematic diagram of indirect enzyme linked immunosorbent assay. 
 
 
 
 
 
a b
e
c
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2.12.2 Procedure   
Different buffers were prepared for ELISA. 
1) Carbonate / bicarbonate buffer 
According to instructions of manufacturer, 2 capsules of carbonate / bicarbonate             
were diluted in sterile water to get a concentration of 100 mM and pH 9.6. 
2) Blocking buffer 
2 % BSA was added in carbonate / bicarbonate buffer and heparin (10 µl per ml of 
buffer) was added to this buffer. 
3) Washing buffer and dilution buffer 1 
0.05 % Tweeen 20 was added to PBS. This washing buffer was also used as 
dilution buffer 1.  
4) Dilution buffer 2 
     2 % BSA was added in the PBS. 
 
 Ninety-six well microtiter plates (Multisorp catalogue no: 446490, Nunc, 
Wiesbaden, Germany) were coated with 125 µl of MBP solution (1 µg MBP diluted 
in 125 µl of carbonate/bicarbonate buffer). After coating, plates were sealed with 
ELISA plate sealer (IBL, Hamburg, Germany) and incubated at 4°C overnight. After 
incubation, plate was washed 3 times with 300 µl of washing buffer per well by 
ELISA Plate washer (Tecan, Crailsheim, Germany). Then blocking was done with 
250 µl of blocking buffer and incubated for 2 hours at RT. After washing, 100 µl of 
3.125, 6.25, 12.5, 25, and 50 ng/ml of monoclonal mouse anti MBP antibody, diluted 
in dilution buffer 1 (Acris Antibodies, Hiddenhausen, Germany) were added in 
duplicate to generate standard curve. In other wells, 100 µl of serum or plasma 
samples diluted 1:667 in dilution buffer 2 were added in duplicate and incubated for 1 
hour at RT. Following washing, 100 µl of Biotin-SP-Conjugated AffiniPure F(ab’)2 
Fragment Goat Anti-Mouse IgG, F(ab’)2 Fragment Specific (Dianova/Jackson, 
Hamburg, Germany) diluted 1:40,000 in dilution buffer 1, was added to each well 
containing monoclonal mouse anti MBP antibody. Moreover, 100 µl of Biotin-SP-
Conjugated AffiniPure Goat Anti-Human IgG, F(ab’)2 Fragment Specific 
(Dianova/Jackson) diluted 1:40,000 in dilution buffer 1, was added to wells 
containing serum samples. All wells were then incubated for 1 hour at RT. Thereafter, 
all wells were washed and 100 µl of the enzyme horseradish peroxidase (HRPO) 
conjugated streptavidin (GE healthcare, Buckinghamsphire, United Kingdom) diluted 
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1:8,000 in dilution buffer 1, was added in each well and incubated for 30 min. After 
washing, 100 µl of substrate tetramethyl benzidine (TMB; Human, Wiesbaden, 
Germany) was added to each well and stored in dark for 2-5 minutes. Then reaction 
was stopped with 100 µl/well with stop solution (Human, Wiesbaden, Germany). The 
optical density of colored product generated by the bound, enzyme-linked detection 
reagents was measured spectrophotometrically using an ELISA plate reader (Tecan) 
at a wavelength of 450 nm with the reference wavelength at 620 nm. The 
concentration of anti MBP antibodies was calculated by generating standard curve 
using concentration of monoclonal mouse anti-myelin basic protein against optical 
density (Systat software, San jose, CA, USA). 
 
2.13 Statistics 
  If not otherwise mentioned, data are given in mean ± standard deviation (SD). 
The comparison of age, sex, number of T lymphocytes and their subpopulations e.g. 
Treg as well as SI values of MS patients with the appropriate values of healthy 
individuals was performed using Wilcoxon two sample tests (Mann Whitney U test). 
Kruskal Wallis test was performed to analyze all parameters for comparison during 
follow up of mitoxantrone therapy in MS patients. Analysis of differences of SI 
values between CD25NEG and CD25MIX within the group of MS patients or healthy 
individuals was calculated by {[(cpm CD25NEG/cpm autologous CD25NEG)/ (cpm 
CD25MIX/cpm autologous CD25MIX)] – 1} and evaluated using the signed rank 
Wilcoxon test. The level of significance was designated as p < 0.05 (two-tailed tests). 
A trend of increase assigned as p value is 0.05-0.1. Spearman’s coefficient of 
correlation was used for correlation analysis. The Statistical Analysis System software 
(SA, Cary, NC, USA) was used to calculate statistical significance.  
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3 Results 
 
3.1  Molecular markers of Treg  
 
3.1.1 CD25 expression 
 
   In human, Treg population exhibits low expression of CD25 to high expression 
as shown in Figure 11, page 45. Therefore, it was difficult to define a distinct 
population using a threshold channel for CD25 expression of Treg.  
  Based on previous measurements done in our laboratory, the threshold value 
of CD25 expression to define Treg was set to > 369 channels (fluorochrome PE). But 
the resulting cell population was a mixture of CD25high and CD25intermediate expressing 
cells as Figure 11, page 45 illustrates. CD25high expression was defined according to 
the CD25 fluorescence intensity of CD8+ T cells in whole blood. We analyzed the 
CD25 expression of CD8+ T cells in all MS patients and healthy individuals. In each 
individual, the highest channel for CD25 expression of CD8+ T cells was defined as 
CD25high. All cells showing higher CD25 expression were CD25high expressing cells. 
Thus, this threshold was used to estimate the percentage of CD25high expressing cells 
of the appropriate Treg population. CD25intermediate was defined between the threshold 
of > 369 channels and CD25high expressing cells.  
  To validate the threshold of Treg > 369 channels, we analyzed isolated Treg and 
CD4+CD25- cells from 10 healthy individuals (Figure 12, page 45). This analysis 
confirmed that most of the Treg are located above the > 369 channels.  
       In our study, we used a magnetic bead separation method to isolate Treg. First, 
CD4+ cells were isolated and then isolated CD4+ cells were used to obtain Treg and 
CD4+CD25- cells. The purity of these isolated cells were analyzed using four color 
flow cytometry and the above defined threshold as shown in Figure 13a, b and c, 
page 46. Purity of isolated Treg (> 369 channels) was calculated from 20 healthy 
individuals and purity was found to be greater than 82 %. 
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Figure 11  A representative example of flow cytometric analysis in whole blood 
showing the threshold of CD25 expression of natural regulatory T cells. 
Threshold defined for natural regulatory T cells to > 369 channels. For 
this analysis CD3+ cells were gated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12  CD25 expression of natural regulatory T cells and CD4+CD25- cells below 
and above the threshold of > 369 channels. 
                    Isolated natural regulatory T and CD4+CD25-cells were stained with CD4 
fluorescein isothiocyante and CD25 phycoerythrin. Events of CD25 
expression were counted in every 40 channels for both isolated cells. 
Mean of events from 10 healthy individuals were taken and then mean 
was plotted against the channels. 
                   Treg: Natural regulatory T cells 
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Figure 13   Flow cytometric analysis showing the purity of isolated cells. 
 After isolation, natural regulatory T cells (Treg) and CD4+CD25- cells were 
 analyzed for their purity by flow cytometry 
    (a) Isolated CD4+  
    (b) Isolated Treg  
    (c) Isolated CD4+CD25- cells 
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3.1.2 HLA-DR expression  
  MS patients may have higher number of activated cells, thus “diluting” the 
number of Treg account for the apparent deficient function in in vitro assays. HLA-DR 
expression of T (CD3+) lymphocytes is an important parameter for activation. In order 
to characterize activation of our isolated Treg, we measured HLA-DR expression in 
our Treg and CD4+CD25high cells from a MS patient. We found that 25 % of isolated 
Treg were HLA-DR positive while 37 % of CD4+CD25high cells were HLA-DR 
positive. This showed that not only CD4+CD25high cells were HLA-DR positive but 
also our CD25intermediate Treg population was HLA-DR positive (Figure 14 a to d, page 
48). In order to compare the whole number of activated T cells, we measured number 
of HLA-DR expressing T cells and their CD4+ and CD8+ subpopulations in whole 
blood of MS patients and healthy individuals. We did not find differences in relative 
number of HLA-DR expressing T cell and their subpopulations between MS patients 
and healthy individuals (Table 3, page 49). Thus, it seems unlikely that our in vitro 
results may be influenced by a “dilution effect”. 
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Figure 14 Flow cytometric analysis showing the HLA-DR expression in natural 
regulatory T (CD4+CD25+) cells and CD4+CD25high (CD4CD25high). 
(a) CD25+ expression of natural regulatory T cells (Treg) and gate for HLA-
DR measurement  
(b) HLA-DR expression of the appropriate gate of (a) 
(c) CD25high expression of regulatory T cells (Treg) and gate for HLA-DR 
measurement  
(d) HLA-DR expression of the appropriate gate of (c) 
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Table 3 Relative number of HLA-DR expressing T lymphocytes and their 
subpopulations in whole blood of 33 healthy individuals and 34 patients 
suffering from multiple sclerosis  
 
T lymphocytes Healthy individuals MS patientsa  p value 
CD3+HLA-DR+ [%] 2.4±0.3b 2±0.2 nsc 
CD3+CD4+HLA-DR+ [%] 1.2±0.1 1.2±0.1 ns 
CD3+CD8+HLA-DR+ [%] 0.9±0.1 0.7±0.1 ns 
 
a MS: Multiple sclerosis 
b All values are given as mean±standard deviation 
c ns: Not significant 
 
 
3.1.3 FOXP3 mRNA expression 
       Recently, it was described that FOXP3 is a unique marker for Treg. Therefore, 
it was important to look for the expression of FOXP3 in our isolated Treg. Thus, we 
measured FOXP3 mRNA expression in Treg and CD4+CD25- cells using real time 
PCR. An example of real time PCR results of mRNA expression in isolated Treg and 
CD4+CD25- is given in Figure 15, page 50. In both MS patients and healthy 
individuals, Treg expressed about 13 fold more FOXP3 gene transcript than 
CD4+CD25- cells (Figure 16, page 51) and confirming again that the isolated Treg 
carry this unique marker.  
  FOXP3 is important for the development and function of Treg. Therefore, 
different FOXP3 amounts could influence the suppressive activity of Treg. Thus, it 
was important to measure FOXP3 gene transcript in MS patients and healthy 
individuals. The amount of FOXP3 gene transcript was not significantly different 
between MS patients and healthy individuals. This showed that changes in Treg 
function between MS patients and healthy individuals were not influenced by FOXP3. 
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Figure 15    An example of real time PCR results showing the threshold cycle value 
of natural regulatory T and CD4+CD25- cells.  
 Natural regulatory T cells (Treg) have less threshold cycle (Ct) value than 
CD4+CD25- for FOXP3. Violet color for CD4+CD25- beta-actin, green 
color for Treg beta-actin, red color for CD4+CD25- FOXP3 and blue 
color for Treg FOXP3. 
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Figure 16    Expression of FOXP3 in natural regulatory T cells (Treg) and CD4+CD25- 
cells of healthy individuals and multiple sclerosis (MS) patients. 
                     The difference in FOXP3 expression was calculated between Treg and 
CD4+CD25- cells as fold difference. 
 
 
3.2 Number of leukocytes and their subpopulations 
3.2.1 Comparison of cell numbers between healthy individuals and MS patients 
Different absolute number of Treg between MS patients and healthy individuals 
may have an impact on the function of these cells. Therefore, it was necessary to 
estimate the absolute Treg number using the number of leukocytes and the relative 
amount of lymphocytes. Leukocyte numbers were found significantly increased while 
lymphocyte numbers significantly decreased in whole blood of MS patients compared 
with healthy individuals (Table 4, page 52). But these changes neither influenced the 
relative number of T lymphocytes and their CD4+ or CD8+ subpopulations nor the B 
lymphocytes. No significant differences could be found in these cells between MS 
patients and healthy individuals in whole blood.  
Treg control autoimmune reactions so it was important to measure the number 
of Treg in MS. It was described that CD8+CD25+ share the phenotypic and functional 
features with Treg. Thus, it was also interesting to measure CD8+CD25+. Relative 
number of both CD25 positive T lymphocytes (CD3+CD25+) and Treg 
(CD3+CD4+CD25+) were significantly increased in whole blood of MS patients 
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compared with healthy individuals. The relative number of CD3+CD8+CD25+ 
lymphocytes tend to be increased in MS patients compared with those of healthy 
individuals. Because some authors had described that CD4+CD25high population as 
Treg, we also measured number of CD4+CD25high cells. But, we did not find significant 
difference between healthy individuals and MS patients.  
Although the leukocyte numbers of the patients was significantly increased 
and the relative amount of lymphocytes was decreased in MS patients compared with 
healthy individuals, the Treg number was increased. That means that a diminshed Treg 
function in the MS patients could not be explained by a decreased number of these 
cells.  
 
Table 4  Number of leukocytes and their subpopulations in whole blood of 33 healthy 
individuals and 34 patients suffering from multiple sclerosis  
  
Parameter Healthy individuals MS patientsa  p value 
Leukocytes [cells/µl] 6091±1917b 7887±2750 0.0012 
Lymphocytes [%]            31±7 24±8 0.0004 
B [cells/µl] 235±152 260±144 nsc 
B [%]             12±5 15±6 ns 
CD3+ [%] 71±1 72±1 ns 
CD3+CD4+ [%] 46±1 47±2 ns 
CD3+CD8+ [%] 23±1 23±1 ns 
CD4+/CD8+ 1.4±1 1.1±0.8 ns 
CD3+CD25+ [%] 17±1 22±2 0.016 
Tregd [%] 15±1 20±1 0.029 
CD3+CD4+CD25high [%]     1±0.5 0.8±0.6 ns 
CD3+CD8+CD25+ [%]   1.4±0.2 2.3±0.4 0.05 
 
a MS:Multiple sclerosis 
b All values are given as mean±standard deviation 
c ns: Not significant 
dTreg: Natural regulatory T cells (CD3+CD4+CD25+) 
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3.2.2 Effect of mitoxantrone (MX) therapy on cell numbers of MS patients 
Mitoxantrone (MX) is an anthracenedione derivative of doxyrubicin which is 
highly effective in the treatment of progressive MS (Hartung et al., 2002). MX acts as 
an immunosuppressant which target proliferating immune cells. To clarify which cell 
type is influenced by MX, we analyzed the effect of MX on number of Treg and other 
immune cells and did follow up studies up to one year with interval of 3 months.  
Leukocytes number and relative number of lymphocytes remain unchanged 
during therapy (Table 5, page 54). There were no significant changes in relative 
number of T cells and their subpopulations (CD4+ and CD8+) and the ratio of 
CD4+/CD8+ following treatment of MX. We also analyzed CD25 expression on T 
cells and their subpopulations. Relative number of CD3+CD25+, Treg and CD8+CD25+ 
cells were also not affected by MX treatment. 
Interestingly, there was a significant decrease in relative and absolute B cell 
numbers at 3 months compared with baseline (before treatment) values and this 
decrease was more pronounced over period of time (Figure 17a and b, page 55). 
Based on these finding, it seems that a persistent and selective reduction of B cell 
numbers occurred following MX treatment but other lymphocytes subpopulations 
remain unaffected by MX therapy. 
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Table 5   Number of leukocytes and their subpopulations in whole blood of patients  
                suffering from multiple sclerosis before and after treatment of mitoxantrone  
 
Parameter 
Baselinea 
(nb=20) 
3 months 
(n=18) 
6 months 
(n=12) 
9 months 
(n=6) 
1 year 
(n=5) 
Leucocytes [cells/µl] 8985±4618c 9974±5333 11386±7428 11816±6338 6632±1861
Lymphocytes [%] 23±8 20±8 21±12 21±13 22±9 
CD3+ cells [%] 74±8 74±10 75±15 75±12 79±9 
CD3+ CD4+ [%] 55±8 54±8 54±12 57±6 56±10 
CD3+ CD8+ [%] 18±4 21±7 21±7 18±6 21±3 
CD4+/CD8+ 3.3±1.2 3±0.9 2.8±0.8 3.5±1.4 2.7±0.7 
CD3+CD25+ [%] 28±19 26±9 26±7 28±10 23±8 
Tregd [%] 26±9 24±9 23±6 26±9 22±8 
CD3+ CD8+CD25+ [%] 2.5±2.2 2.3±1.9 2.6±2.6 2.4±1.9 1.3±0.7 
 
 
a Baseline (before treatment) 
b n: Number of patients with multiple sclerosis 
c All values are given as mean±standard deviation; 
dTreg: Natural regulatory T cells (CD3+CD4+CD25+) 
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Figure 17  Relative (a) and absolute (b) number of B cells of multiple sclerosis 
patients before and during therapy with mitoxantrone.  
  Numbers were shown as mean±standard deviation. Zero months 
represents before treatment and 3, 6, 9, 12 months represents after 
treatment of mitoxantrone. n represents number of patients. 
                * p < 0.05 vs. zero months 
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3.3  Function of Treg  
  Treg control autoimmune reactions so it was important to examine the function 
of these cells in MS patients. As a possible target of this autoimmune reaction, myelin 
basic protein (MBP) has been the most widely studied myelin antigen. Thus we used 
MBP as an antigen and as a control pokeweed mitogen (PWM) for stimulation. 
 
3.3.1 Optimization of the antigen concentration and cell numbers for the  
       proliferation assay 
3.3.1.1 Determination of MBP concentration 
 We tested different concentrations of MBP in four healthy individuals. For this 
purpose, peripheral blood monocytes (PBMCs) were stimulated with different 
concentrations of MBP and proliferation was measured by 3H-thymidine 
incorporation as counts per minute. We included as a control PBMCs without any 
antigenic or mitogenic stimulation (autologous) in order to estimate the intrinsic 
capacity of proliferation because some of the T cells included in the PBMCs were 
preactivated. To take this autologous proliferation in consideration, the stimulation 
index (SI) equal to the values of stimulated cultures/autologous cultures was 
calculated. Four µg/well of MBP concentration was the best concentration for 
stimulation (Figure 18). In our cultures, we used 5 µg MBP/well. 
 
 
 
 
 
 
 
 
 
 
Figure 18  Myelin basic protein induced proliferation of peripheral blood 
mononuclear cells. 
    1 x 105 peripheral blood mononuclear cells were stimulated with 
different concentrations of myelin basic protein (MBP). Data are 
shown as mean+SD.  
     SI: Stimulation index 
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3.3.1.2  Determination of PBMCs number  
   We tested different number of PBMCs using MBP for stimulation in one 
healthy individual. 2 x 105 cell numbers showed the best proliferation. But, these cell 
numbers were always difficult to obtain from the MS patients (Figure 19). Therefore, 
we should use less PBMCs in the cultures. 0.5 x 105 and 1 x 105 PBMCs/well showed 
measurable proliferation. Because, we needed some more cells to measure additional 
parameters e.g. TNF-α expression, we chose 1 x 105 PBMCs/well in the proliferation 
assay. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19  Proliferation of peripheral blood mononuclear cells from one healthy  
   individual. 
Different number of peripheral blood mononuclear cells was stimulated 
with 4 µg/well of myelin basic protein. 
PBMCs: Peripheral blood mononuclear cells 
SI: Stimulation index 
 
3.3.1.3  Determination of isolated Treg and CD4+CD25- numbers  
   We tested different number of isolated Treg or CD4+CD25- for proliferation 
in seven healthy individuals. First, we added 1x105 PBMCs per well and then we 
added different numbers of isolated Treg or CD4+CD25- cells (Figure 20 and 21, page 
58). 2.5 x 103 and 10 x 103 of Treg or CD4+CD25- cells showed the best proliferation. 
We used 10 x 103 of both cells in order to increase the effect of theses cells.  
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Figure 20 Proliferation of natural regulatory T cells stimulated with 4 µg/well of 
myelin basic protein.  
In all wells, first, 1x105 peripheral mononuclear cells were added and then 
different cell number of natural regulatory T cells was added. Data are 
shown as mean + SD. 
SI: Stimulation index  
Treg: Natural regulatory T cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21 Proliferation of CD4+CD25- cells stimulated with 4 µg/well of myelin 
basic protein.  
In all wells, first, 1x105 peripheral mononuclear cells added and then 
different cell numbers of CD4+CD25- cells were added. Data are shown as 
mean + SD.  
SI: Stimulation index 
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3.3.2  Suppressive activity of Treg  
      To address the question that Treg are proliferative in nature, Treg from two 
healthy individuals and two MS patients were cultured alone without any stimulation 
(autologous) and with antigen (MBP) or mitogen (PWM). We found no difference in 
proliferation between cultures with and without MBP addition. In contrast, PWM-
induced proliferation was increased compared with autologous values. So, Treg 
proliferation was dependent from the conditions. 
  In order to establish that the antigen MBP and the mitogen PWM-induced 
proliferation values of PBMCs plus CD4+CD25- (CD25NEG) should be different 
from the autologous values, we compared these values. Indeed, statistical analysis 
revealed that mitogen (PWM) and antigen (MBP)-induced proliferation of CD25NEG 
from MS patients as well as healthy individuals was significantly different from the 
appropriate autologous values (Table 6). This was also true if we added Treg in 
CD25NEG (Table 7, page 60). 
 
Table 6 Proliferation of peripheral blood mononuclear cells plus CD4+CD25- 
(CD25NEG) cell without (autologous) and with addition of myelin basic 
protein or pokeweed mitogen from 19 healthy individuals and 29 multiple 
sclerosis patients 
              3H-thymidine uptake [cpma] 
  Autologous MBPb PWMc 
Healthy individuals 363±317d 1074±1252e 53398±22755e 
MSf patients 327±268 940±1072e 63089±36940e 
 
acpm: Counts per minute 
bMBP: Myelin basic protein 
cPWM: Pokeweed mitogen 
dAll values are given as mean±standard deviation  
ep<0.05 compared with appropriate autologous values 
fMS: Multiple sclerosis 
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Table 7 Proliferation of peripheral blood mononuclear cells plus CD4+CD25- and 
Treg (CD25MIX) without (autologuous) and with addition of myelin basic 
protein or pokeweed mitogen from 19 healthy individuals and 29 multiple 
sclerosis patients 
             3H-thymidine uptake [cpma] 
  Autologous MBPb PWMc 
Healthy individuals 482±411d 797±687e 49299±24633e 
MSf patients 373±264 894±804e 63274±34355e 
 
acpm: Counts per minute 
bMBP: Myelin basic protein 
cPWM: Pokeweed mitogen 
dAll values are given as mean±standard deviation  
ep<0.05 compared with appropriate autologous values 
fMS: Multiple sclerosis 
 
 
Now, we looked if there was a difference in proliferation in MS patients and 
healthy individuals between cultures without (CD25NEG) and with (CD25MIX) Treg. 
Proliferation was significantly reduced in cultures containing Treg compared to those 
without addition of Treg in healthy individuals. This was true for the antigen MBP as 
well as mitogen (PWM)-induced proliferation (Figure 22 a and b, page 61). These 
results confirmed that the isolated Treg were able to suppress antigen and mitogen-
induced proliferation and fulfilled the functional requirements for isolated Treg. 
In contrast to healthy individuals, we found that MBP stimulated cultures 
containing Treg of MS patients did not show significantly reduced proliferation 
compared with those without Treg. Although, PWM-induced proliferation was 
significantly diminished in Treg containing cultures compared with those without Treg; 
this effect was less pronouced compared with healthy individuals. Thus, Treg in MS 
patients showed reduction or loss of suppressive activity. 
There was another difference between MS patients and healthy individuals in 
PWM-induced proliferation. The proliferation of Treg containing cultures of the MS 
patients was significantly increased compared with the appropriate values of the 
healthy individuals. That may be due to an increased proliferative activity of Treg.  
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Figure 22 Pokeweed mitogen (a) and myelin basic protein (b) induced proliferation of 
CD25NEG and CD25MIX. 
1x105 peripheral blood mononuclear cells plus 1x104 CD4+CD25- cells 
were cultured in absence (CD25NEG) or presence of 1x104 natural 
regulatory T cell (CD25MIX). The bars extend from the 25th percentile to 
the 75th percentile with a horizontal line at the median. Whiskers extend to 
the smallest value up to the largest.  
n represents number of multiple sclerosis (MS) patients and healthy 
individuals. 
PWM: Pokeweed mitogen  
MBP: Myelin basic protein 
*p < 0.05 vs. CD25NEG 
** p < 0.05 vs. CD25MIX of healthy individuals  
SI: Stimulation index 
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Data obtained from MS patients displayed a broad range in proliferation and 
suggested that the functional activity of Treg may differ between individual MS 
patients. Therefore, the suppressive activity of Treg was calculated individually and 
compared. The percentage of suppression of Treg (CD25MIX) was calculated by 
setting the SI values of CD25NEG cultures to 100 % proliferation. 
In PWM-induced co-cultures, Treg from healthy individuals (21 of 23 cases, 91 
%) showed a trend to higher suppressive activities (chi square test; p = 0.086) 
compared with MS patients (20 of 29 cases, 69 %) (Figure 23, page 63). In addition, 
Treg of 13 out of 29 MS patients (45 %) suppressed MBP-induced proliferation 
(Figure 24, page 64), this was significantly (chi square test; p = 0.022) less than Treg 
from healthy individual (17 out of 19, 89 %). In contrast to healthy individuals, Treg of 
55 % (MBP-induced proliferation) and 31 % (PWM-induced proliferation) MS 
patients showed loss of suppression. 
  Treg suppressive function using PWM and MBP-induced proliferation was 
significantly correlated in healthy individuals (r = 0.49, p = 0.0349) as well as in MS 
patients (r = 0.61, p = 0.0005). 
 63
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23 Suppressive function of natural regulatory T cells in pokeweed mitogen 
induced proliferation.  
To assess the functional activity of regulatory T cells (Treg), 1 x 105 
peripheral blood mononuclear cells plus 1 x 104 CD4+CD25- cells were 
cultured in absence (CD25NEG) or presence of 1 x 104 Treg (CD25MIX) in 
healthy individuals or multiple sclerosis (MS) patients. Pokeweed mitogen 
(PWM) was used for stimulation. 
n represents number of multiple sclerosis patients and healthy individuals. 
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Figure 24 Suppressive function of natural regulatory T cells in myelin basic protein 
induced proliferation.  
To assess the functional activity of regulatory T cells (Treg), 1 x 105 
peripheral blood mononuclear cells plus 1 x 104 CD4+CD25- cells were 
cultured in absence (CD25NEG) or presence of 1 x 104 Treg (CD25MIX) in 
healthy individuals or multiple sclerosis (MS) patients. Myelin basic 
protein (MBP) was used for stimulation. 
n represents number of multiple sclerosis  patients and healthy individuals. 
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3.3.3 Effect of MX on suppressive activity of Treg 
  As described earlier in section 3.3.2, we found the loss of suppressive activity 
of Treg in MS patients. Hence, we assumed that MX therapy may restore the loss of 
suppressive activity of Treg. 
  We did the proliferation analysis to measure the suppressive activity up to 9 
months after MX therapy and compared it with the baseline (before treatment) values. 
We did not find any significant difference in suppressive activity of Treg in MBP and 
PWM-induced proliferation (Figure 25 and figure 26, page 66) during therapy 
compared with baseline values. Thus, MX therapy did not restore the loss of 
suppressive activity in MS patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25 Suppressive function of natural regulatory T cells in pokeweed mitogen 
induced proliferation.  
To assess the functional activity of natural regulatory T cells (Treg), 1 x 105 
peripheral blood mononuclear cells plus 1 x 104 CD4+CD25- cells were 
cultured in absence (CD25NEG) or presence of 1 x 104 Treg (CD25MIX) in 
multiple sclerosis (MS) patients. Pokeweed mitogen (PWM) was used for 
stimulation.  
Zero months represents before treatment. 
 n represents number of MS patients 
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Figure 26 Suppressive function of natural regulatory T cells in myelin basic protein 
induced proliferation. 
To assess the functional activity of natural regulatory T cells (Treg), 1 x 
105 peripheral blood mononuclear cells plus 1 x 104 CD4+CD25- cells 
were cultured in absence (CD25NEG) or presence of 1 x 104 Treg 
(CD25MIX) in multiple sclerosis (MS) patients. Myelin basic protein 
(MBP) was used for stimulation. 
Zero months represents before treatment.  
n represents number of MS patients. 
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3.4  Role of TNF-α production in Treg function  
       Mechanism of Treg mediated suppression is still less understood. So in order to 
elucidate the mechanism of Treg mediated suppression, we measured the TNF-α 
production in CD3+ and CD4+ cells in four MS patients and five healthy individuals. 
First, PBMCs plus CD4+CD25- cells were cultured in absence (CD25NEG) or 
presence (CD25MIX) of Treg and then stimulated with PWM. After 5 days of cultures, 
we collected the cultured cells and then performed intracellular staining to measure 
the TNF-α expression in proliferating CD3+ and CD4+ cells in cultures with and 
without Treg. We also tried to measure it in autologous cultures and MBP stimulated 
cultures, but we could not measure TNF-α production because of less proliferation. 
An example of flow cytometric measurement of TNF-α is shown in Figure 27, page 
68. We also did proliferation assay to measure Treg mediated suppression as described 
in section 3.3. 
   In MS patients, we found correlation between Treg mediated suppression and 
TNF-α production. In three MS patients, loss of suppression is related to increase in 
TNF-α production while in one patient, there is Treg mediated suppression with less 
TNF-α production (Table 8, page 69).  
In contrast to MS patients, we did not find any correlation between Treg 
mediated suppression and TNF-α production. Out of four healthy individuals with 
having suppression, two had increased and two had decreased TNF-α production 
(Table 8, page 69). We had seen earlier in section 3.3.2 that 91 % of healthy 
individuals showed Treg mediated suppression in PWM-stimulated cultures. Thus, we 
chose one healthy individual with no suppression to look for TNF-α production and 
we found a decrease in TNF-α production. In this healthy individual, percentage of 
suppression is not correlated with TNF-α production as we had found in MS patients. 
These results demonstrated that involvement of TNF-α production in Treg mediated 
suppression may differ between MS patients and healthy individuals. 
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Figure 27  An example of flow cytometric measurement of tumor necrosis factor-α   
expression. 
(a) R1 and R2 gate represents proliferating and non-proliferating cells. 
(b) R3 gate represents CD3 positive cells which are gated from R1 
(c) CD3+ against isotype control (Gated on R1 and R3) 
(d) CD3+ against tumor necrosis factor TNF-α which shows TNF-α 
positive cells CD3+ cells (Gated on R1 and R3) 
(e) CD4+ against isotype control (Gated on R1 and R3) 
(f) CD4+ against TNF-α which shows TNF-α positive cells CD4+ cells 
(Gated on R1 and R3) 
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Table 8  Difference in relative numbers of tumor necrosis factor-α positive CD3+ and 
CD4+ cells on the peripheral blood mononuclear cells plus CD4+CD25-
without (CD25NEG) and with (CD25MIX) Treg population after 
proliferation with pokeweed mitogen-stimulated cultures and percentage of 
suppression 
 
Patient/Healthy a% of ∆CD3+ b% of ∆CD4+ cSuppression 
Patient1 14 18 No
Patient2  4  5 No 
Patient3 19 17 No 
Patient4 -54 -59 Yes
    
Healthy1 36 45 Yes 
Healthy2 -15 -16 Yes 
Healthy3 48 49 Yes 
Healthy4 -4 -0.5 Yes 
Healthy5 -5 -14 No 
 
                    a∆CD3+ = (TNF-α positive CD3+ of CD25MIX) - (TNF-α positive CD3+ of            
                                CD25NEG) 
                    b∆CD4+ = (TNF- α positive CD4+ of CD25MIX) - (TNF-α positive CD4+ of   
                                 CD25NEG) 
                   c Suppression is percentage of suppression of PWM induced proliferation 
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3.5  Detection of antibodies against MBP 
  Autoimmunity is also detectable by measurement of auto antibodies. Thus, we 
compared concentrations of autoantibodies the CNS-restricted antigens (MBP) in 
serum of MS patients and healthy individuals. At the time when we established this 
assay, no human anti MBP antibody was available. Therefore, we quantitated these 
autoantibodies from a standard curve generated using a monoclonal antibody (first 
antibody) from the mouse directed against human MBP. An example of this standard 
curve is shown in Figure 28. Co-efficient of intra-assay variation was calculated by 
running plasma sample 10 times in one assay. The co-efficient of intra-assay variation 
was 12 %.  
      We did not find significant difference in anti MBP antibodies concentration 
between serum of healthy individuals and MS patients (Figure 29, page 71). 
Although, MBP antibodies is involved in the pathogenesis of MS but their 
concentrations were not elevated in MS patients compared with healthy individuals. 
We compared the anti MBP antibodies in MS patients and percentage of Treg mediated 
suppression but we did not find any correlation. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure  28 An example of standard curve generated using different concentrations of 
   monoclonal mouse anti-myelin basic protein against optical density. 
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Figure 29   Concentration of anti myelin basic protein antibodies in multiple sclerosis 
patients and healthy individuals. 
    Concentration of anti myelin basic protein antibodies in serum were 
estimated from standard curve generated from monoclonal mouse anti-
myelin basic protein. 
n represents number of multiple sclerosis (MS) patients or healthy 
individuals. 
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 4  Discussion 
 
In this study, we proved that natural regulatory T cells (Treg) obtained from a 
magnetic bead isolation method has phenotypical and functional characteristics. We 
found a reduction or loss of suppressive activity of Treg in the patients suffering from 
multiple sclerosis (MS) compared with healthy individuals using an optimized antigen 
[myelin basic protein (MBP)] and mitogen [pokeweed mitogen (PWM)]-induced 
proliferation assay. This may be explained by a reduction in number of these cells 
and/or a disruption of Treg function of a single cell. 
 
4.1      Comparison of cell numbers between healthy individuals and MS patients 
Diminished suppressive activity of Treg cannot be due to a lack of these cells 
because when compared with healthy individuals, MS patients had a significantly 
higher relative number of Treg in their peripheral blood. Moreover, it cannot be 
explained by alterations in T cell populations as we did not find significant 
differences in number of T cells and their subpopulations (CD4+ and CD8+ and their 
ratio CD4+/CD8+). 
Our finding of an increase in relative number of Treg in MS patients compared 
with healthy individuals, were in contrast to previous findings. Three studies (Haas et 
al., 2005; Putheti et al., 2004; Viglietta et al., 2004) did not report significant changes 
in frequency of CD25high cells between MS patients and healthy individuals. When the 
analyses were extended to CD25intermediate cells (Haas et al., 2005) or CD4+CD25+ 
(including all CD25+) cells (Putheti et al., 2004), comparable number of Treg in MS 
patients and healthy individuals were found. On the other hand, it was shown that MS 
patients had significantly reduced relative number of CD4+CD25+ T cells (Khoury et 
al., 2000). 
One possible explanation may be that different subgroups of MS patients were 
included in the studies. The MS patients analyzed in our study had a mean age of 40 
years, an average disease duration of 7.4 years and a mean EDSS of 3.7. The clinical 
features are representative for MS patients with a relapsing remitting or secondary 
progressive MS (Limmroth et al., 2006). 
 
    Another possible explanation for this discrepancy could be the definition of 
Treg based on the level of CD25 expression. It has always been a matter of discussion 
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to define Treg in human because CD25 expression of Treg is not distinct. Some studies 
have shown that only CD25high expressing cells are Treg. We defined Treg by a 
threshold for CD25 expression of > 369 PE fluorescence channels. Using this 
threshold, we did not include only CD25high cells expressing but also CD25intermediate 
cells. When we restricted our analysis to CD4+CD25high cells which was only 1 % of 
CD3+ (CD25high were gated according to > than CD25 fluorescence intensity of CD8+ 
T cells), we also did not find significant differences in CD4+CD25high cells in MS 
patients compared with healthy individuals. 
    Treg may be defined by additional markers such as HLA-DR or FOXP3. 
Baecher-Allan et al. (2001) reported that expression of HLA-DR was restricted to 
CD25high lymphocytes so we measured HLA-DR expression on our isolated Treg and 
our defined CD25high expressing Treg population. We found that 25 % of our isolated 
Treg were HLA-DR positive while 37 % of CD4+CD25high cells were HLA-DR 
positive. This concluded that in our isolated Treg,, the CD25high and CD25intermediate 
expressing cells were HLA-DR positive. 
  In our study, determination of FOXP3 mRNA message in Treg revealed a 13-
fold higher expression compared to the appropriate CD4+CD25- cell population of MS 
patients as well as healthy individuals. Our results were in concordance with the 
findings by Haas et al. (2005) who reported nearly the same ratio of FOXP3 mRNA 
expression between CD25high as Treg and CD4+CD25- cells. 
  An interesting aspect of definition of Treg is the recently published observation 
that Treg showed decrease in CD127 expression (Hartigan-O'Connor et al., 2007). 
 
Aside from the increased number of Treg in MS patients compared with healthy 
individuals, we also found a tendency of increased in numbers for the CD8+CD25+ 
cell population. This may be of interest because CD8+CD25+ thymocytes with 
regulatory function and a phenotype similar to Treg including FOXP3 expression was 
previously described (Cosmi et al., 2003). This activity also found in peripheral blood 
T cells, too (Jarvis et al., 2005). 
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4.2 Function of Treg 
An important aspect of our study was the measurement of suppression activity 
of Treg. Previous studies have shown that an autoimmune T-cell response to myelin 
antigens is thought to be involved in MS pathogenesis (Martin and McFarland, 1995; 
Ota et al., 1990). As a possible target of this autoimmune reaction, MBP has been the 
most widely studied myelin antigen, so we used MBP as an antigen and as a control 
PWM as mitogen in an optimised assay using 3H-thymidine uptake as a measure for 
suppression of proliferation.  
 
For our in-vitro assay, we used peripheral blood mononuclear cells (PBMCs) 
plus CD4+CD25- cells, which were cultured in absence (CD25NEG) or presence 
(CD25MIX) of Treg. We added CD4+CD25- cells in PBMCs for two reasons; first, in 
order to increase the number of MBP specific responder T cells and second, as a 
control because some cells may get activated during isolation procedure.  
 
We had used immunodensity and immunomagnetic separation procedure 
which involves anti-CD25 antibody-coupled magnetic beads to isolate our Treg 
population. In Treg consisting of a mixture of CD25high and CD25intemediate cells, we 
observed suppressive activities up to 80 % in co-cultures from healthy individuals. 
These data suggested but finally could not prove that the functional activity of 
CD25high and a mixture of CD25high and CD25intemediate cells may be comparable. But, 
recently one group also used the same isolation procedure and reported that bead-
sorted which is a mixture of CD25high and CD25intemediate and FACS sorted CD25high T 
cells showed comparable levels of suppression for both MS patients and healthy 
individuals (Venken et al., 2006). 
Suppressive activity of the mixture of CD25high and CD25intemediate , is also 
supported by the findings of Wing et al. (2003), who analyzed CD4+CD25+ 
expressing cells. They reported that 40 % of the cells showing bright 
immunofluorescence (i.e. including intermediate CD25 expressing cells) were 
probably suppressive for myelin oligogodendrocyte glycoprotein (MOG)-induced 
proliferation in healthy individuals. They used an immunomagnetic separation 
procedure to obtain Treg by positive selection, while we isolated CD4+ lymphocytes by 
a negative selection procedure. Due to the low number of Treg in the peripheral blood 
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and the selection procedure it was not possible to compare the functional activity of 
Treg with high or intermediate CD25 expression directly.  
 
4.2.1 Mitogen and antigen- induced proliferation assays 
A significant decrease in the suppressive activity of Treg lymphocytes 
expressing CD25high has been shown  in mitogen e.g. anti-CD3 and anti-CD28 
polyclonal stimulated cultures of lymphocytes from MS patients (Viglietta et al., 
2004). We also observed an overall decrease in the functional activity of Treg in 
mitogen (PWM)-stimulated cultures in 31 % MS patients. This finding was also 
confirmed in antigen (MOG)-stimulated cultures using isolation procedure similar to 
us (Haas et al., 2005). Moreover, in our MBP (antigen)-stimulated co-cultures, Treg 
obtained from about 89 % of healthy individuals displayed suppressive activity 
whereas 55 % of MS patients showed no suppressive Treg function. 
 Mitogen stimulation may be less efficient to detect impaired activity of Treg in 
MS patients. As shown in our study, suppressive activity was lost to a higher degree 
in MBP-antigen induced cultures than in PWM stimulated cultures. We cannot judge 
from the publication by Haas et al. (2005), whether in MOG-driven responses 
functional activity of Treg is lacking in all patients. A failure in the regulation of 
MBP-specific responses may have more impact on the pathogenic process than 
regulation of MOG-specific responses. This was underlined by our observation that 
in contrast to antigen-induced proliferation, the proliferation of Treg containing 
cultures stimulated with mitogen of the MS patients was significantly increased 
compared with the appropriate values of the healthy individuals. This may be 
explained by different mechanisms of suppressive activity of Treg in antigen or 
mitogen-induced proliferation.  
 
A loss of the functional activity of Treg in MBP-stimulated cultures from MS 
patients may explain the manifestation and maintenance of the disease. So far, we 
have no explanation for the failure of Treg in MS patients.  
Several factors could account for the deficient function of Treg in MS patients. 
First, a higher frequency of MBP reactive T cells in MS patients compared with 
healthy individuals may explain the loss of suppression in MBP-induced proliferation. 
But so far, according to Hong et al. (2004), estimation of MBP-reactive T cells has 
been inconclusive. Another explanation may be that MS patients have higher number 
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of activated cells, thus “diluting” the number of Treg may account for the apparent 
deficient function in in vitro assays. Therefore, we measured HLA-DR expression of 
T lymphocytes as an important parameter for the activation. We did not find 
significant differences in the relative number of HLA-DR expressing T cells between 
MS patients and healthy individuals so it seems unlikely that our in vitro results may 
be explained by a “dilution effect”.  
Huan et al. (2005) reported a higher proliferation rate of Treg from MS patients 
compared with healthy individuals. Moreover, the authors provide evidence that 
proliferating Treg are less suppressive than non-proliferating Treg. We also found that 
cultures containing Treg (CD25MIX) cells have higher PWM-induced proliferation 
compared with healthy individuals. These findings may explain a surplus of 
proliferation in those MS patients who present with a complete loss of the functional 
activity of Treg. These data support our observation that MS patients compared with 
healthy individuals harbour proliferating albeit non-functional Treg.  
One possible explanation may also be that suppression is influenced by 
demographic parameters. Therefore, we compared suppressing activity of Treg with 
diseases duration, age of onset and EDSS of MS patients but we did not find any 
correlation.  
  FOXP3 is important for the development and function of Treg. Therefore, 
different FOXP3 amounts could influence the suppressive activity of Treg. Thus, it 
was important to measure FOXP3 gene transcript in MS patients and healthy 
individuals. The amount of FOXP3 gene transcript was not significantly different 
between MS patients and healthy individuals. This showed that changes in Treg 
function between MS patients and healthy individuals were not influenced by FOXP3. 
Haas et al. (2005) also found no difference in FOXP3 expression between MS patients 
and healthy individuals. However, there was one report on decreased FOXP3 levels of 
CD4+CD25+ lymphocytes in MS patients (Huan et al., 2005). The possible 
explanation for this discrepancy might be that the MS patients they analyzed probably 
belonged to a different subgroup. These patients had average disease durations of 15.3 
years compared with 7.4 ± 6.9 years in our study. 
Another aspect is that aside the natural CD3+CD4+CD25+FoxP3+ Treg several 
other FoxP3+ and non-FoxP3+ subsets of induced suppressor T cells (Tr1, Th3) are 
also players of the immune tolerance network (Wing et al., 2006). Since, we used 
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PBMCs in our in vitro system we could not absolutely exclude that suppression of 
Treg might be influenced by other such cells.  
  
4.2.2 Role of TNF-α production in Treg function 
The exact mechanism of suppression by Treg is not well understood. 
Accumulating evidences suggest that Treg suppress effector T cell proliferation 
through a cell contact dependent manner and cytokine independent mechanism 
(Piccirillo et al., 2002; Suri-Payer and Cantor, 2001; Takahashi et al., 1998). But still 
it is not clear whether cytokines are involved in Treg suppression or not. In order to 
elucidate the mechanism of suppression, we measured TNF-α production in cultures 
with and without Treg using intracellular staining by flow cytometry.  
Due to less proliferation in autologous and MBP-induced cultures, it was 
difficult to detect TNF-α production. So, we measured TNF-α production in PWM-
induced cultures. Interestingly, we found different results in MS patients and healthy 
individuals. Out of four MS patients, three patients showed increased in TNF-α 
production after addition of Treg. In these patients, we found loss of suppression. 
While in one patient we found decrease in TNF-α production after addition of Treg, 
and patients showed suppressive activity of Treg. This shows that TNF-α production 
had an inverse relation with Treg function. This result was in concordance with one 
recent study in which it was shown that anti-TNF-α therapy in rheumatoid arthritis 
generates a newly differentiated population of Treg, which compensates for defective 
Treg. We (Mueller et al., 2003) and Bo et al.(2001) found that impaired proliferative 
responses to mitogens may be due to a high local production of TNF-α. With these 
result it can be deduced that defect in Treg function may be due to increase in TNF-α 
production. 
In contrast to MS patients, we found different results in healthy individuals. 
We did not find any correlation between percentage of suppression and TNF-α 
production. This indicated that involvement of TNF-α production in Treg mediated 
suppression may differ between MS patients and healthy individuals. 
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4.2.3 Antibodies against MBP 
Antibody production by mature B lymphocytes, plasma cells, is the final stage 
of an immune response. Thus, antibody production should also be influenced by Treg 
function. MBP is one of the target proteins in MS pathogenesis. Therefore, we 
developed an assay for measurement of anti MBP antibodies.  
Accumulating evidences suggest that an antibody-mediated process may have 
an important role in the pathogenesis of MS (Raine et al., 1999; Storch et al., 1998). 
Autoantibodies recognizing several myelin proteins including MBP (Newcombe et 
al., 1985; Olsson et al., 1990; Paterson et al., 1981; Sellebjerg et al., 1995), 
proteolipid protein (Sellebjerg et al., 1995; Warren and Catz, 1994) and Myelin 
oligogodendrocyte glycoprotein (MOG) are present in MS patients (Baig et al., 1991; 
Moller et al., 1989), but their role in disease progression is enigmatic and 
controversial.  
 
MBP is one of the widely studied target proteins in MS pathogenesis hence we 
analyzed autoantibody against MBP.  The detection of anti MBP antibodies in serum 
of MS patients has been elusive. This difficulty may  in part be related to a tendency 
to form immune complexes which hampers their detection (Dasgupta et al., 1983). 
We referred to the established ELISA method utilized by Chamczuk et al. (2002) and 
performed some modification in order to increase the sensitivity of the assay.  
In our study we did not detect any significant difference in anti MBP 
antibodies between serum of healthy individuals and MS patients. This result was in 
contrast to the group who established this ELISA method where they reported that 77 
% MS patients had elevated levels of anti MBP antibodies (Chamczuk et al., 2002). 
Using western blot techniques, anti MBP antibodies were detected in 28 % MS 
patients (Reindl et al., 1999). Other studies also reported the presence of anti MBP 
antibodies (Terryberry et al., 1998; Vojdani et al., 2003), while in some studies they 
were not detected (Brokstad et al., 1994; Colombo et al., 1997; Olsson et al., 1990). 
One possible explanation for this discrepancy may be that either MS patients we 
analyzed in our study probably belong to a different subgroup or we have taken a 
small cohort of MS patients.  
We did not detect any correlation between anti MBP antibodies and Treg 
mediated suppression. 
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4.3    Effect of mitoxantrone on number of Treg and other immune cells as  well  
 as on Treg function 
In the second part of our study, we investigated the long-term effect of 
mitoxantrone (MX), a potent disease modifying drug for MS treatment, on the number 
of Treg and other immune cells in MS patients. We assumed that MX therapy may 
restore the impaired function of Treg, hence, we measured effect of MX on suppressive 
activity of Treg. 
 
4.3.1 Cell numbers 
Several investigations were performed in order to elucidate the mode of action 
of MX. It was reported that MX induces decrease in lymphocytes number by 
induction of apoptosis (Chan et al., 2005). However, the data on whether MX 
selectively affects specific subpopulations is contradictory. Chan et al. (2005) and 
Gbadamosi et al. (2003) reported preferential cell death of CD8+ T cells. In this study, 
we showed that MX did not lead to a longstanding reduction of number of CD4+ or 
CD8+ T cells, neither in the beginning (3 months post first infusion) nor in the later 
course of the treatment. The main difference of our study compared to the previous 
investigations was that we performed our analyses 3 months after MX was applied 
while others focused on short-term effects (1 hour up to 14 days) (Chan et al., 2005; 
Gbadamosi et al., 2003). It assumed that a decrease of CD8+ cells occurs along with 
general leukopenia in the first weeks after MX treatment, but that these cells recover 
afterwards. Acute leukopenia generally resolved one month post infusion. This 
assumption was supported by recent finding (Pelfrey et al., 2006) who came to a 
similar conclusion when they analyzed MX effects one month after infusion and did 
not find a reduction of CD4+ or CD8+ T cells in patients with primary progressive 
MS. A previous study that focused on short term effects of mitoxantrone also reported 
some long-term in vivo effects of MX in MS (Gbadamosi et al., 2003). The 
investigators did not find a significant change of CD8+ T cells up to 6 months. More 
data on CD8+ cells were from a longitudinal study by Gonsette (1996). This group 
found a selective reduction of CD4+CD45+ cells with relative sparing of CD8+ cells, 
which resulted in a decreased CD4+/CD8+ ratio during MX therapy up to 3 years. But 
in our study, we did not find significant difference in CD4+/CD8+ ratio.  
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MX is known to cause a transient leukopenia, but its effect on leukocyte 
subsets are less understood. Therefore, we examined number of leukocytes and 
relative number of lymphocytes but we did not find effect of MX on number of 
leukocytes and lymphocytes. This showed that long-term effect of MX was not 
associated with leukopenia. Pelfrey et al. (2006) also showed the same as they did not 
find change in number of lymphocytes. 
 
Our longitudinal data showed that MX led to a significant decrease of B cell 
numbers that could be measured as early as 3 months after the first cycle (mean 
reduction; relative number: 34 % and absolute number: 41 %). This effect was not 
only sustained during additional treatment cycles but it became more significant 
(mean reduction; relative number: 87 % and absolute number: 89 %) after 12 months. 
The finding of a preferential reduction of B cells was in line with several previous 
investigations. A preferential reduction of B cells was also found by Gbadamosi et al. 
(2003) who reported on 8 patients with 3-4 MX cycles at 2-3 months intervals. In 
contrast to our study, the effect reached statistical significance only after 6 months, 
which might be due to the fact that the patient number in the earlier study was small. 
Mauch et al. (1992) and also Gonsette (1992) reported a decrease of B cell numbers 
after one year during or/and also after cessation of MX therapy. Although the 
treatment protocols in some of the earlier studies were different from the most widely 
used ones nowadays, it seems that the current treatment regimen had a comparable 
effect on lymphocyte subpopulations. 
In agreement with previous findings, our study underlines that the long-term 
effects of MX in the treatment of MS could preferentially be mediated by targeting B 
cells. Fidler et al. (1986) demonstrated that MX reduces splenic B lymphocytes in 
mice with inhibition of antibody response to thymic dependent and thymic 
independent antigens (Fidler et al., 1986a). In vitro treatment of malignant leukemia 
cells with MX revealed that MX induces apoptosis (Bellosillo et al., 1998; Bhalla et 
al., 1993). Inhibition of non-antigen-specific proliferation of activated peripheral 
blood lymphocytes (both T and B cells) as well as antigen-specific T cell lines by MX 
in dose dependent manner were reported (Neuhaus et al., 2005). This group also 
showed that MX induces apoptotic cell death at low concentrations and necrotic cell 
death at high concentrations. In our study we did analysis with numbers of T cells but 
did not find influence of MX on these cells. Based on these finding, it seems that a 
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persistent and selective reduction of B cell numbers occur but other lymphocytes 
subpopulation remain unaffected by MX therapy. 
 
We also measured the behaviour of Treg number during MX therapy. We had 
shown earlier that relative number of Treg was increased in MS patients compared to 
healthy individuals so; we assumed that MX might effect relative number of Treg. On 
the contrary, we did not find any significant difference in Treg frequency during MX 
treatment in vivo. Thus far, the effects of disease modifying drugs on Treg in peripheral 
blood have not much known. One publication (Putheti et al., 2004) in agreement with 
us reported that Treg remain unaffected during ongoing treatment with IFN-ß-1a or GA 
or IFN-ß-1a+GA. They also did follow-up of MS patients before and during IFN-ß-1a 
treatment but there were no changes in the proportions of Treg. Recently, another 
publication showed that there was trend of increasing proportions of Treg after 6 
months of IFN-ß-1a therapy when compared with the baseline (de Andres et al., 
2007).  
 
 
4.3.2  Suppressive function of Treg 
 We had also measured the effect of MX on suppressive capacity of Treg. As 
we described earlier that in PWM and MBP-stimulated cultures, there was decrease or 
loss in functional activity of Treg in MS patients. So, we assumed that MX may restore 
the Treg suppressive activity. Interestingly, we did not observe any persistent effects of 
MX on functional activity of Treg up to 9 months compared with baseline values. The 
knowledge about the effect of immunomodulatory drug on Treg function is very much 
limited. Recently, it has been reported that suppressive activity of Treg is significantly 
enhanced after 3 and 6 months of IFN-ß-1a therapy (de Andres et al., 2007). But, still 
effect of MX on function and frequency of Treg in MS patients has not reported.  
The comparison of Treg mediated suppressive function between healthy 
individuals and MS patients revealed that MS patients had impaired function, 
although B cell numbers and anti MBP antibodies between both groups were not 
different. So, it could be that impaired Treg function in MS patients effects interaction 
between effector cells or interaction between antigen presenting cells and not between 
B cells. In contrast, we found that MX influences the B cell numbers and not the Treg 
function. 
 82
As a summary, it can be concluded that MX does not exhibit a persistent effect 
on the numbers or suppressive capacity of Treg but that its potent effect on MS disease 
activity is predominantly, although not exclusively, mediated by a suppression of 
humoral immunity. 
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5         Summary 
 
Multiple sclerosis (MS) is considered to be an autoimmune disorder directed 
against self antigens of the central nervous system e.g. myelin basic protein (MBP). 
Natural CD4+CD25+FoxP3+ regulatory T cells (Treg)-mediated active suppression is 
an essential mechanism in the control of self-antigen reactive cells and in the 
induction of peripheral tolerance in vivo.  
In this study, we proved that our isolated Treg has phenotypical and functional 
characteristics. We found a reduction or loss of suppressive activity of Treg in the 
patients suffering from multiple sclerosis (MS) compared with healthy individuals.  
In our study, we set the threshold for CD25 expression of Treg to > 369 
channels which was a mixture of CD25high and CD25intemediateexpressing cells, Treg may 
be defined with the other markers such as FOXP3 and HLA-DR. Analyzing HLA-DR 
expression on our isolated Treg and CD25high showed that 25 % of our isolated Treg 
were HLA-DR positive while 37 % of CD4+CD25high cells were HLA-DR positive. 
This concludes that our CD25intermediate Treg population was also HLA-DR positive. In 
our study, determination of FOXP3 mRNA message in Treg revealed a 13-fold higher 
expression compared to the appropriate CD25 negative cell population of MS patients 
as well as healthy individuals.  
We studied whether changes in the suppressive function of a mixture of 
CD25high and CD25intemediate expressing Treg in myelin basic protein (MBP)-and PWM-
induced proliferation occurred in untreated MS patients compared with healthy 
individuals. Suppression of MBP-induced proliferation was observed in 13 out of 29 
(45 %) MS patients; this was significantly less compared with 17 out of 19 (89 %) 
healthy individuals. In pokeweed mitogen-induced co-cultures, Treg from healthy 
individuals (21 of 23 cases, 91 %) showed a trend to higher suppressive activities (p = 
0.086) compared with MS patients (20 of 29 cases, 69 %). 
We also looked for changes in relative Treg number and found that they were 
significantly increased in MS patients (mean±SD; 20±8 %) compared with healthy 
individuals (15±5 %). 
The exact mechanism of suppression by Treg is not well understood. In order to 
elucidate the mechanism, we measured tumor necrosis factor (TNF)-α production 
intracellulary after 5 days in PWM stimulated cultures. We found that in MS patients, 
TNF-α production had an inverse relation with Treg function. It seems that defect in 
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Treg function may be due to increase in TNF-α production. In contrast to MS patients, 
we found different results in healthy individuals. We did not find any correlation 
between percentage of suppression and TNF-α production. This showed that 
involvement of TNF-α in Treg mediated suppression mechanism might differ in MS 
patients and healthy individuals. 
Antibody production by mature B lymphocytes and plasma cells is the final 
stage of an immune response. Thus, antibody production should also be influenced by 
Treg function. MBP is one of the target proteins in MS pathogenesis. Therefore, we 
developed as assay for measurement of anti MBP antibodies. We did not find any 
significant difference in anti MBP antibodies between healthy individuals and MS 
patients.  
In the second part of our study, we investigated the long-term effect of 
mitoxantrone (MX), a potent disease modifying drug for MS treatment, on the number 
of Treg and other immune cells in MS patients. We found a persistent and selective 
reduction of B cell numbers occur during therapy but other lymphocytes 
subpopulation remains unaffected. 
We assumed that MX therapy may restore the impaired function of Treg so we 
measured effect of MX on suppressive activity of Treg. But we did not find a persistent 
effect of MX on functional activity of Treg up to 9 months compared with baseline.  
Comparative analysis of Treg mediated suppressive function between healthy 
individuals and MS patients revealed that MS patients had impaired function, 
although B cell numbers and anti MBP antibodies between both groups were not 
different. Thus, it could be that impaired Treg function in MS patients effects 
interaction between effector cells or interaction between antigen presenting cells but 
not between B cells. In contrast, we found that MX influences the B cell numbers and 
not the Treg function. 
As a summary, it can be demonstrated that MX does not exhibit a persistent 
effect on the number or suppressive capacity of Treg but its potent effect on MS 
disease activity is predominantly, although not exclusively, mediated by a suppression 
of humoral immunity. 
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